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Ateroskleroosin erilaiset komplikaatiot, kuten sydäninfarkti ja aivohalvaus, kuuluvat 
yleisimpiin kuolinsyyn aiheuttajiin länsimaissa. Ateroskleroottisten plakkien kehittymistä 
edistävät monet eri prosessit kuten LDL-kolesterolin kertyminen verisuonten seinämiin, 
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lihassolujen proliferaatio, jota säätelee useat solusyklin säätelyproteiinit. Sykliinistä 
riippuvaiset kinaasit (cyclin dependent kinase, CDK) ovat tärkeitä solusyklin säätelijöitä. Ne 
muodostavat aktiivisen kompleksin sykliinien kanssa ja fosforyloivat kohdeproteiinejaan, 
jotka osaltaan edistävät solusykliä. Sykliinien lisäksi CDK:n toimintaa säätelevät CDK:n 
inhibiittoriproteiinit, aktivoiva ja estävä fosforylaatio, proteolyysi ja monet transkriptiotekijät. 
Solusyklin tarkka säätely on välttämätöntä. Solusyklin häiriintynyt säätely onkin monien 
sairauksien, kuten syövän, ateroskleroosin, restenoosin ja aivojen rappeumasairauksien, 
taustalla. Lääkehoidon kohdistaminen solusyklin säätelyproteiineihin on noussut mielen-
kiintoiseksi lähtökohdaksi näiden sairauksien hoidossa. Kliinisissä kokeissa tutkitaankin 
useiden pienimolekyylisten CDK:n estäjien vaikutuksia.  
Tyloforiini on fenantroindolitsidiinialkaloidi, jonka on osoitettu estävän useiden syöpä-
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1 INTRODUCTION 
 
Complications of atherosclerosis are the primary cause of death in Western societies 
(Lusis 2000). Atherosclerotic lesions contribute to development of thrombosis, which 
result in myocardial infarction or stroke. The development of atherosclerotic lesions is a 
complex process and a number of questions remain incompletely answered. However, 
vascular smooth muscle cell (VSMC) proliferation is one of the processes contributing 
to lesion formation. Various cell cycle regulatory proteins control this proliferation. 
 
The mammalian cell division is a series of events that are tightly regulated by numerous 
regulatory proteins. Cell cycle is divided into four phases: G1, S, G2 and M phase 
(Figure 1) (Nurse 2000). During the first gap phase (G1), cells are preparing for the 
DNA replication in S phase (synthesis). In the second gap phase (G2), cells are 
preparing for the division between two identical daughter cells in M phase (mitosis). 
The first three phases are called interphase. Most of the cells in an adult organism are 
not dividing, thus they are in a quiescent phase called G0. 
 
Each cell cycle phase and transition is controlled by protein kinases called cyclin 
dependent kinases (CDKs) (Malumbres and Barbacid 2005). Various CDKs are orderly 
activated at specific phases of the cell cycle. Despite CDKs, cyclins and cyclin 
dependent kinase inhibitors (CKIs) are crucial for proper cell cycle progression. This 
tight regulation of cell cycle is essential; thus its deregulation is connected to the 
development of cancer and other proliferative disorders such as atherosclerosis and 
restenosis as well as neurodegenerative diseases. 
 
Proteins of the cell cycle provide potential and attractive targets for new drug 
development in treatment of these proliferative disorders. Consequently, various low 
molecular weight CDK inhibitors have been identified and are in clinical development 
(Diaz-Padilla et al. 2009). Most of these studies of CDK inhibitors have focused on 
treatment of cancer, although the relevance of cardiovascular and neurodegenerative 
diseases have increased. 
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2 CELL CYCLE AND CELL PROLIFERATION 
 
2.1 Progression through the cell cycle 
 
Progression through the cell cycle requires cells to advance through the specific 
checkpoints (Hartwell and Weinert 1989; Elledge 1996). The best defined checkpoints 
are DNA damage, DNA replication and spindle-assembly checkpoints. This checkpoint 
concept blocks the cell cycle for instance, when the cells have not successfully 
completed the previous phase or DNA is damaged. These transitions are tightly 
controlled by various regulatory proteins, of which CDKs play a major role (Figure 1) 
(Malumbres and Barbacid 2005; Morgan 1997). CDKs are inactive without binding to 
their regulatory subunits, cyclins. Activated CDK-cyclin complexes contribute cell 
cycle by phosphorylating serine-threonine amino acids of their substrate proteins. 
 
The initiation of cell cycle depends on extracellular cues such as mitogens and nutrient 
availability as well as intracellular cues (Malumbres and Barbacid 2005; Morgan 1997). 
For example, platelet-derived growth factors (PDGFs) are mitogens involved in 
development of various cell types (Andrae et al. 2008). The expression of D-type 
cyclins, regulators of G1 initiation and progression, depends on mitogenic stimulation. 
Before entering the cycle, cells must pass certain checkpoints for example to ensure 
their homeostatic size to be sufficient. 
 
Retinoblastoma protein (Rb) is an important regulator of cell cycle progression from G1 
to S phase (Cobrinik 2005; Weinberg 1995). Rb and its relatives p107 and p130 are 
tumour suppressor proteins that comprise the family of so-called pocket proteins. The 
loss of Rb was originally identified in rare pediatric eye tumour, retinoblastoma (Friend 
et al. 1986). Furthermore, it was found to be mutated in various cancers such as 
osteosarcoma, breast cancer and small cell lung cancer (Friend et al. 1986; Harbour et 
al. 1988; Lee et al. 1988). Rb plays a fundamental role in cellular regulation (Cobrinik 
2005; Weinberg 1995). Its phosphorylation by CDK-cyclin complexes is required for 
cell cycle progression. 
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Figure 1. The mammalian cell cycle is divided into four phases: G1, S, G2 and M. G0 is 
a quiescent phase. The initiation of cell cycle in G1 is regulated by cyclin D-CDK4/6 
complexes, which start Rb phosphorylation that is continued by cyclin E-CDK2 
complexes. Rb becomes hyperphosphorylated, and releases the E2F transcription 
factors, which promotes the transcription of genes that contribute to cell cycle. Cyclin 
A-CDK2/1 and cyclin B-CDK2 complexes regulate the subsequent G2-M phase. Cyclin 
dependent kinase inhibitors INK4, p21 and p27 control the activation of cyclin-CDK 
complexes. p53 directly activates p21 (adapted from Boehm and Nabel 2001, 
Malumbres and Barbacid 2001). 
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In G0 cells, Rb is unphosphorylated or hypophosphorylated and interacts with 
transcription factors of E2F family (Flemington et al. 1993; Helin et al. 1993). It 
represses transcription of genes that are important for cell cycle progression by binding 
and inhibiting E2Fs. This repression of E2F regulated genes mediates G0-G1 cell cycle 
arrest. In humans, several E2Fs act in transcriptional regulation (Trimarchi and Lees 
2002). E2F1, E2F2 and E2F3 are potent transcriptional activators inhibited by Rb, 
whereas E2F4 and E2F5 act as transcriptional repressors that interact with p107 and 
p130. 
 
In G1 phase, cyclin D-CDK4/6 and later cyclin E-CDK2 complexes increasingly 
phosphorylate Rb (Cobrinik 2005). Hyperphosphorylated Rb releases repression of E2F, 
which promotes transcription of genes, including cyclin E, cyclin A and cyclin B. A 
positive feedback loop is created, when E2F induce cyclin E, which pairs with CDK2 
and further phosphorylates Rb. This stage in late G1 has been defined as the restriction 
point, after which cells are able to undergo cell division without mitogenic 
stimulus. Furthermore, in late G1, cyclin E-CDK2 complex phosphorylates also other 
substrates required for the S phase entry. 
 
In S phase, the amount of E-type cyclins decreases and CDK2 binds to A-type cyclins 
(A1 and A2) (Malumbres and Barbacid 2005; Morgan 1997). This complex 
phosphorylates various proteins involved in exit from S phase. In G2 phase, the level of 
cyclin A starts to decrease and the amount of B-type cyclins (B1 and B2) increases. 
They associate with CDK1 and together form a complex called M phase promoting 
factor during G2 and M phase. CDK2 and CDK1 maintain Rb in a hyperphosphorylated 
form until the end of M phase. In addition, Cyclin C-CDK3 complex may promote G0-
G1 transition by stimulating the phosphorylation of Rb (Helin et al. 1993). 
 
2.2 Cyclin dependent kinases 
 
The first CDK was originally identified in cell division cycle mutation studies in 
budding yeast Saccharomyces cerevisiae and in fission yeast Schizosaccharomyces 
pombe (Hartwell et al. 1974; Nurse et al. 1976). In both studies, one gene was found to 
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be essential for cell cycle progression: Cdc28 in S. cerevisia and Cdc2 in S. pombe. The 
human homolog of the proteins encoded by these genes was identified and later named 
CDK1 (Lee and Nurse 1987). Over ten genes encoding CDKs have been identified in 
the mammalian genome (Malumbres and Barbacid 2005; Lapenna and Giordano 2009). 
 
Cell cycle progression has been assumed to be one of the major roles of CDKs (Table 1) 
(Malumbres and Barbacid 2005). However, only five CDKs have been directly 
implicated in this function. Generally, it is believed that CDK1 is involved in mitosis, 
whereas CDK2-CDK4 and CDK6 play roles in interphase.  
 
Table 1. Major CDKs and cyclins in humans (adapted from Morgan 1997, Malumbres 
and Barbacid 2005). 
 
CDK Cyclin partner (preferred partner underlined) Function 
CDK1 Cyclin B, Cyclin A, Cyclin E, Cyclin D Cell cycle: M 
CDK2 Cyclin A, Cyclin E, Cyclin B, Cyclin D Cell cycle: G1, S, G2 
CDK3 Cyclin E, Cyclin A, Cyclin C Cell cycle: G0, G1, S 
CDK4 Cyclin D Cell cycle: G1 
 CDK5 p35, p39 Neuronal differentiation 
CDK6 Cyclin D Cell cycle: G1 
CDK7 Cyclin H CAK, transcription 
CDK8 Cyclin C Transcription 
CDK9 Cyclin T, Cyclin K Transcription, cell cycle: G2, M 
CDK10 - Transcription, cell cycle: M 
CDK11 Cyclin L, Cyclin D Transcription 
 
 
Regulation of transcription is another significant function of CDKs. CDK7 and cyclin H 
form CDK activating kinase (CAK) (Fisher 2005). This complex regulates the activity 
of other CDKs during cell cycle. In addition, it is a component of TFIIH (transcription 
initiation factor IIH). Furthermore, CDK8-Cyclin C and CDK9-Cyclin T phosphorylate 
the carboxyterminal domain of the large subunit of RNA polymerase II, thus regulating 
transcription (Garriga and Graña 2004; Rickert et al. 1996). CDK8-Cyclin C also 
regulates transcription by phosphorylating cyclin H leading to inhibition of TFIIH 
(Akoulitchev et al. 2000). CDK5 differs from other CDKs and is activated by non-
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cyclin proteins, p35 and p39 (Dhariwala and Rajadhyaksha 2008). It plays a major role 
in regulation of central nervous system by phosphorylating a number of proteins 
involved in transcription, neuronal function, migration and synaptic transmission. 
 
New knowledge gathered from knock-out animals has challenged some previous 
hypotheses of cell cycle progression (Malumbres and Barbacid 2005; Sherr and Roberts 
2004). Genetic studies in mice lacking a specific CDK have revealed that not all CDKs 
are strictly essential for the cell cycle progression. In addition, CDKs can, at least 
partly, compensate for each other’s function. However, some CDKs have been shown to 
be essential for development of specific types of cells or tissues. 
 
CDK2 has been assumed to be a crucial regulator of S phase. However, mice lacking 
CDK2 are viable and healthy but infertile (Berthet et al. 2003; Ortega et al. 2003). 
These results suggest that CDK2 is dispensable for the mitotic cell cycle but essential 
for meiosis. The loss of CDK2 activity might be compensated by CDK1 associating 
with A- or E-type cyclins (Santamaría et al. 2007). Thus, CDK1 seems to be essential 
for cell cycle progression. 
 
CDK4 and CDK6 have been shown to be dispensable for cell cycle of most cell types 
(Malumbres et al. 2004). Accordingly, mice lacking CDK4 or CDK6 are viable, but 
these ablations affect the proliferation of certain specialized cells. Mice lacking CDK4 
are small, and most males and all females are sterile (Rane et al. 1999; Tsutsui et al. 
1999). In addition, these mice develop insulin-dependent diabetes, since loss of CDK4 
inhibits the postnatal proliferation of pancreatic -cells. Ablation of CDK6 results in 
mild defects in hematopoiesis indicating the role of CDK6 in hemocytes (Malumbres et 
al. 2004). 
 
2.3 Cyclins 
 
Cyclins were originally identified from fertilized sea urchin eggs, as proteins that are 
constitutively synthesized and destroyed at each cleavage division (Evans et al. 1983). 
Consequently, cyclins are rather unstable proteins, whose expression fluctuates during 
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the cell cycle, whereas CDKs are expressed relatively constantly through the cell 
division (Morgan 1997). Owing to the changes in cyclin levels, different CDK-cyclin 
complexes are activated in the specific phase of the cell cycle.  
 
Such as CDKs, only certain cyclins are essential for cell cycle progression and the 
essentiality of different isoforms of cyclins varies between cell types (Sherr and Roberts 
2004). Mice lacking cyclin D1 are viable, but they are small and exhibited defective 
development of retina and breast tissue (Fantl et al. 1995; Sicinski et al. 1995). Mice 
lacking all three D-type cyclins develop until mid or late gestation, but die due to severe 
anemia combined with a cardiac output failure (Kozar et al. 2004). However, mice 
develop normally to midgestation, suggesting that cell cycle without D-type cyclins is 
possible. Mice expressing only one D-type cyclin (D1, D2 or D3) die before or soon 
after birth (Ciemerych et al. 2002). During early embryonic development the residual 
cyclin is upregulated in most of the tissues. However, some tissues, in which cyclin was 
not upregulated, exhibited severe abnormalities later in gestation. For example, the loss 
of cyclin D1 in retinas was not compensated by cyclin D2 or D3. 
 
Mice lacking one cyclin E gene (E1 or E2) are viable, but loss of both genes leads to 
lethality at late embryonic stage on account of defective endoreplication of trophoblasts 
(Geng et al. 2003). Loss of cyclin A2 leads to embryonic lethality, whereas cyclin A1 is 
required for meiosis in male mouse, but not for mitosis (Liu et al. 1998; Murphy et al. 
1997). Cyclin B1 is essential for cell cycle, since its ablation leads to embryonic 
lethality, whereas mice lacking cyclin B2 develop normally (Brandeis et al. 1998). 
 
 
3 REGULATION OF CDK ACTIVITY 
 
The cell cycle control system involves complex series of biochemical signals and 
processes, which all contribute or inhibit the cell cycle progress (Morgan 1997). For 
instance, besides cyclins, CDK activity is modulated by various means including 
activating and inhibitory phosphorylation, transcription factors, proteolysis and 
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endogenous CKIs. However, the initiation of cell cycle also requires the stimulative 
signals outside the cell. 
 
3.1 Signalling pathways 
 
Extracellular signalling pathways involve mitogens that stimulate cell division 
(Malumbres and Barbacid 2005; Sherr and Roberts 2004). Most of them, for instance 
PDGF and epidermal growth factor (EGF), act broadly stimulating various cell types. 
Mitogens interact with many different receptor tyrosine kinases and G protein-coupled 
receptors, thus activating multiple intracellular signalling pathways, which further 
trigger the entry and progression through the cell cycle. Major signalling pathways are 
mediated through Ras oncogene or lipid kinase, phosphoinositol 3’kinase (PI3K) 
(Massagué 2004). 
 
Various Ras signalling pathways play an important role in initiation of cell cycle 
(Massagué 2004; Sears and Nevins 2002). Mitogenic stimulation activates cell-surface 
receptors leading to phosphorylation of their tyrosine residues on the cytoplasmic 
domain. This activation creates docking sites for adaptor proteins that trigger effectors 
such as Ras to the membrane. Binding to GTP activates Ras leading to recruitment of 
other effectors. Phosphorylation of various effectors contributes to signal downstream 
cascades. One of these cascades is Ras-Raf-MAPK (mitogen activated protein kinase) 
(Campbell et al. 1998). Furthermore, MAPK phosphorylates c-Myc on Ser-62 leading 
to its stabilization (Sears et al. 2000). 
 
c-Myc is an important transcription factor contributing the entry to the cell cycle 
(Adhikary and Eilers 2005). It belongs to Myc family of transcription factors that 
regulates a significant number of genes involved in cell proliferation, growth and 
apoptosis. They induce the expression of D-type cyclins by binding to their partner 
protein, Max (Myc-associated factor x) (Bouchard et al. 1999). In addition, they 
suppress the expression of CDK inhibitors, p21 and p15, in association with another 
transcription factor, Miz1 (Myc-interacting protein 1), thus stimulating the entry to G1 
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(Seoane et al. 2002; Staller et al. 2001). They have also been indicated in activation of 
RNA polymerases (Gomez-Roman et al. 2003; Grandori et al. 2005). 
 
Another signalling pathway is mediated through PI3K. It is recruited to the cell 
membrane due the activation of cell-surface receptor or substrate, such as insulin-like 
receptor substrate (Vivanco and Sawyers 2002). In addition, activation of Ras can 
trigger PI3K to the membrane. PI3K binds to phospho-tyrosine sites of receptors or 
substrates and generates PIP3 (phosphatidylinositol-3,4,5-triphosphate) in the 
membrane. PIP3 functions as a second messenger to activate downstream pathways by 
triggering cell cycle regulatory proteins such as mTOR (mammalian target of 
rapamycin) and Akt (protein kinase B). 
 
Akt is a serine/threonine kinase acting as an important regulator of many biological 
processes such as proliferation and apoptosis (Datta et al. 1999). For example, 
activation of Akt contributes CDK activity by inhibiting glycogen synthase kinase-3β 
(GSK-3β) (Cross et al. 1995). GSK-3β phosphorylates cyclin D1 on Thr-286, which 
triggers a rapid cyclin D1 degradation by ubiquitin-dependent proteolysis (Diehl et al. 
1998). In addition, GSK-3β redirects cyclin D1 subcellular localization from the nucleus 
to the cytoplasm. Therefore, GSK-3β inhibition by Akt leads to cyclin D1 accumulation 
contributing cell cycle progression. Furthermore, GSK-3β phosphorylates c-Myc on 
Thr-58 facilitating its proteolysis by the ubiquitin pathway and colocalizes with c-Myc 
in the nucleus (Gregory et al. 2003). 
 
Extracellular signals can also prevent cell cycle initiation and cell proliferation, thereby 
maintaining tissue homeostasis (Massagué 2004). Transforming growth factor-β (TGF-
β) is a cytokine, which in mature cells leads to cytostasis or apoptosis (Massagu  1998; 
Shi and Massagué 2003). TGF-β activates membrane-receptor serine/threonine kinases 
that phosphorylate SMAD proteins. The founding member of the SMAD family was 
first identified as the product of the Drosophila gene Mad (mothers against dpp) 
(Sekelsky et al. 1995). Shortly, three Mad homologues were identified in C. elegans as 
cytoplasmic signal transducers and called sma-2, -3, and -4 (Savage et al. 1996). Many 
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homologues were then defined in vertebrates and named SMADs (for SMA MAD 
related) (Massagu  1998). 
 
Proteins of the SMAD family are tumour suppressors that play an important role in the 
transduction of receptor signals to target genes in the nucleus (Massagu  1998; Shi and 
Massagué 2003). Activated SMAD proteins accumulate in the nucleus and form 
transcriptional complexes. These complexes target different genes contributing G1 
arrest by various mechanisms. For example, the activation of TGF-β increases 
expression of CDK inhibitors, p21 and p15 (Reynisdottir et al. 1995). TGF-β also 
inhibits Myc, thus inhibiting gene transcription that contributes to the cell cycle (Seoane 
et al. 2001). 
 
3.2 Ubiquitylation and proteasomal degradation of CDKs 
 
Protein degradation through ubiquitin-mediated proteolysis plays an important role in 
cell cycle regulation targeting various cell cycle regulatory proteins, including cyclins 
and CKIs (Reed 2003; Weissman 2001). Ubiquitylation is a covalent conjugation of 
ubiquitin to target proteins for degradation by a proteasome. It is a multistep process 
that involves several ATP-dependent enzymes including an ubiquitin-activating enzyme 
(E1), an ubiquitin-conjugating enzyme (E2) and an ubiquitin protein ligase (E3). 
Ubiquitylation is mediated through two strategies. Proteins can be degraded via 
activation of the target substrate itself or activation of the ubiquitin protein ligase that 
transfers ubiquitin to a particular class of target. 
 
Target-activated degradation is most commonly carried out by E3 ligase SCF 
(Skp/Cullin/F-box protein) and depends on the regulatory context of individual target 
molecules (Reed 2003; Weissman 2001). F-box proteins, such as SKP2 and Cdc4, 
recognize phosphorylated substrates, thus acting as substrate-specificity factors of SCF 
complexes. For example, phosphorylated p21 and p27 are recognized by F-box protein 
SKP2 leading to their degradation (Bornstein et al. 2003; Carrano et al. 1999). 
Furthermore, Cdc4 binds to cyclin E contributing to its ubiquitin-mediated proteolysis 
(Strohmaier et al. 2001). 
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On the contrary, APC/C (anaphase-promoting complex/cyclosome) is responsible for 
ligase activation, which enables total degradation of target molecule populations (Reed 
2003; Weissman 2001). Activation of APC/C requires the activity of two alternative co-
factors: Cdc20 (cell division cycle protein 20) or Cdh1 (Cdc20 homolog 1). Cdc20 is 
synthesized in late cell cycle. Cdh1 is expressed constitutively, but it is negatively 
regulated by phosphorylation; for example, by CDKs. Both of these co-factors are 
involved in degradation of cyclin A and cyclin B (Sudakin et al. 1995). 
 
3.3 p53 
 
p53 protein is the major regulator of stress response pathways in cells, and thus an 
important regulator of cell cycle arrest and apoptosis (El-Deiry 1997; Levine 1997; 
Ryan et al. 2001). Besides its role in cell cycle arrest and apoptosis, its activation can 
induce several other responses in cells, including differentiation, senescence, DNA 
repair and inhibition of angiogenesis. Many types of cellular stress can activate p53, 
including DNA damage, hypoxia, oncogene activation, oxidative stress and change in 
normal growth and survival signalling.  
 
p53 is a transcription factor that activates numerous target genes (Kruse and Gu 2009; 
Laptenko and Prives 2006). For example, in order to induce cell cycle arrest in G1, it 
directly activates the cyclin dependent kinase inhibitor p21 (Deng et al. 1995; El-Deiry 
et al. 1993). In contrast, G2 arrest requires multiple effector target genes (Taylor and 
Stark 2001). p53 induces apoptosis by regulating multiple downstream targets both in 
the mitochondrial and in the death-receptor-induced apoptotic pathways (Ryan et al. 
2001). For example, it mediates the induction of pro-apoptotic members of the Bc1-2 
family, including Bax (Bcl-2 associated X protein) and PUMA (p53 upregulated 
modulator of apoptosis) (Miyashita and Reed 1995; Nakano and Vousden 2001). These 
proteins trigger cytochrome c release leading to activation of APAF1 (apoptotic 
protease activating factor 1) and further to apoptotic cascade (Srinivasula et al. 1998). 
p53 also induces the expression of death receptors, such as Fas (TNF superfamily 
receptor 6) and Killer/DR5 (death receptor 5) or mediates their relocalization to the cell 
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surface contributing to apoptosis (Bennett et al. 1998; Owen-Schaub et al. 1995; Wu et 
al. 1997). 
 
Since p53 is such a potent inhibitor of cell growth, there are several regulatory 
mechanisms to control its stability, subcellular localization, activity, transcription and 
translation (El-Deiry 1997; Levine 1997; Ryan et al. 2001). 
 
One of the major regulators of p53 is MDM2 (murine double minute 2) protein, 
responsible for its degradation by various mechanisms (Brooks and Gu 2006). MDM2 is 
E3 ubiquitin ligase that target p53 leading to its ubiquitylation and further degradation 
by the proteasome (Haupt et al. 1997; Honda et al. 1997). In addition, MDM2 can 
inhibit transcriptional activity of p53 and direct its nuclear export. However, MDM2 
activation is also regulated by several mechanisms (Brooks and Gu 2006). DNA-
damage-induced checkpoint kinases Chk1 and Chk2 phosphorylate p53, which inhibits 
MDM2 to bind p53 and thus prevents the degradation of p53 (Shieh et al. 2000). 
Tumour suppressor protein ARF (alternative reading frame) is another inhibitory 
mechanism of MDM2 activity (Pomerantz et al. 1998). After oncogene activation ARF 
protein binds and inhibits MDM2 directly.  
 
p53 function depends on its nuclear localization, which is tightly regulated by nuclear 
import and export mechanisms (Ryan et al. 2001). Microtubule network and dynein is 
involved in its nuclear import (Giannakakou et al. 2000). p53 also contains leucine-rich 
nuclear export signal located in its C-terminal region regulating its nuclear import 
(Stommel et al. 1999). 
 
In addition, p53 is regulated by a number of post-translational modifications both during 
normal homeostasis and in stress-induced responses (Kruse and Gu 2009). These 
modifications include phosphorylation, acetylation, methylation and sumoylation. For 
instance, phosphorylation of p53 on Ser-46 controls its ability to induce expression of 
the apoptotic target gene p53AIP1 (p53 apoptosis inducing protein 1) (Oda et al. 2000). 
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3.4 Cyclin dependent kinase inhibitors 
 
Endogenous CKIs are classified into two families: INK4 (inhibitors of CDK4) family 
and CIP/KIP (CDK interacting protein/Kinase inhibitory protein) family, based on their 
structure and target CDKs (Sherr and Roberts 1999). The INK4 family, including p16, 
p15, p18 and p19, binds specifically to monomeric CDK4 and CDK6. The CIP/KIP 
family, including p21, p27 and p57, binds more broadly to various cyclin and CDK 
subunits (Table 2). CIP/KIP family members inhibit the activity of CDKs by binding to 
the adenosine triphosphate (ATP) binding site, therefore blocking the ATP binding. The 
INK4 family members bind both N- and C-terminal lobes of CDK inducing allosteric 
changes. These modifications block cyclin binding and also reduce the binding of ATP. 
 
Initially, CKIs were considered only as negative regulators of cell cycle, but 
paradoxically CIP/KIP proteins act also as positive regulators (Cheng et al. 1999; 
Labaer et al. 1997). CIP/KIP proteins inhibit the activity of CDK2, but activate CDK4 
and CDK6. Cyclin D-CDK4/6 complexes bind and sequester CIP/KIP proteins. This 
interaction stabilizes and directs the transport of cyclin D-CDK4/6 complexes into the 
cell nucleus and relieves cyclin E-CDK2 from CIP/KIP constraint, thereby increasing 
their activation (Sheaff et al. 1997; Vlach et al. 1997). Furthermore, when the level of 
effective CIP/KIP proteins is decreased enough, cyclin E-CDK2 can trigger the 
degradation of p27, thus facilitating its own activation (Carrano et al. 1999). When p27 
is phosphorylated by cyclin E-CDK2, it is degraded through ubiquitylation by SCF. 
When mitogenic stimulation ceases, cyclin D levels fall and the tethered CIP/KIP 
proteins are released (Sherr and Roberts 1999). They bind and inhibit the activity of 
cyclin E-CDK2 complexes leading to G1 arrest. Accumulation of INK4 proteins can 
also disrupt cyclin D-CDK complexes and release CIP/KIP proteins, and when 
overexpressed even lead to cell cycle arrest in G1.  
 
Regulation of CKIs is complex and they are induced in response to various cellular 
processes (Sherr and Roberts 1999). For instance, p15 is induced by TGF-β contributing 
to G1 phase arrest (Hannon and Beach 1994). p27 expression increases in absence of 
extracellular mitogens or in response to anti-mitogenic signalling, which contribute to 
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cell cycle arrest by inhibition of cyclin E-CDK2 (Blain et al. 2003). p21 is activated by 
tumour suppressor protein p53 (Chen et al. 1995; Harper et al. 1993). Activation of p53 
after DNA damage leads to transcriptional induction of p21, which inhibit the activity 
of CDK2 leading to cell cycle arrest in G1 or apoptosis. Besides its role as an effector of 
p53, p21 has been implicated in numerous biological processes. For instance, p21 can 
bind and inhibit PCNA (proliferating-cell nuclear antigen), which is a subunit of DNA 
polymerase-δ, thus involved in DNA replication (Waga et al. 1994). This inhibition 
suppresses the DNA synthesis until DNA repair is finished. 
 
Table 2. CDK inhibitors and their targets (adapted from Sherr and Roberts 1999). 
 
 Synonyms Targets 
INK4 family 
p16 INK4a 
CDK4 
CDK6 
p15 INK4b 
p18 INK4c 
p19 INK4d 
CIP/KIP family 
p21 Cip1, Waf1 
CDK1, CDK 2, CDK 4, CDK 6 
Cyclin A, Cyclin B, Cyclin D, Cyclin E 
p27 Kip1 
p57 Kip2 
 
 
3.5 Phosphorylation 
 
The activity of CDKs is also regulated by activating and inhibitory phosphorylation 
(Morgan 1997). CAK, consisting of CDK7 and cyclin H, is essential for the activity of 
most CDKs by phosphorylating a threonine residue (Thr-172 in CDK4, Thr-160 in 
CDK2) (Fisher and Morgan 1994; Lolli and Johnson 2005). On the contrary, the activity 
of CDKs is inhibited by phosphorylation on threonine and tyrosine residues by 
regulatory kinases such as Myt1 (myelin transcription factor 1) (Mueller et al. 1995). 
Cdc25 (cell division cycle 25) phosphatases can dephosphorylate these residues and 
thus trigger entry into mitosis.  
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4 CDKS IN HUMAN DISEASES 
 
4.1 Cancer  
 
The role of CDKs and their regulators has been extensively studied in cancer (Sherr 
1996; Lapenna and Giordano 2009; Malumbres and Barbacid 2009). Alterations 
particularly in CDKs have been reported quite infrequently but in a wide variety of 
tumours. However, other cell cycle regulators are frequently mutated in human cancer 
leading to misregulation of CDK activity. These alterations result in uncontrolled cell 
proliferation and aberrant cell division. Predictably, proteins that drive the cell cycle, 
such as cyclins, are often overexpressed in primary tumours, whereas proteins that 
inhibit cell cycle, including CKIs, are inactivated. Cell cycle regulators interact together 
in extensive and complex network; thus in most cases, expression of more than one 
protein is altered. Consequently, the primary cause of cancer or the significance of a 
single regulatory protein is difficult to assess. 
 
CDK4 is mutated in a few cases of familial melanoma by a miscoding mutation that 
blocks binding of INK4 inhibitors (Wolfel et al. 1995). In addition, CDK4 is amplified 
or overexpressed in several malignancies, such as breast cancer tumours, sarcomas and 
glioblastomas (An et al. 1999; Khatib et al. 1993; Schmidt et al. 1994). CDK6 is 
overexpressed in some lymphomas in response of nearby translocations (Corcoran et al. 
1999; Hayette et al. 2003).  
 
Most human tumours carry mutations or alterations in regulators of CDKs including D- 
and E-type cyclins and CDK inhibitors (Malumbres and Barbacid 2001; Malumbres and 
Barbacid 2009). In addition, mutations that activate mitogenic signalling pathways are 
common in cancer. For instance, mutations that cause hyperactivation or overexpression 
of Ras or Myc proteins, promote cell growth, proliferation and further development of 
cancer (Downward 2003; Nilsson and Cleveland 2003).  
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Cyclin D1 is one of the most prevalent cell cycle regulators implicated in the 
development of various cancer types (Deshpande et al. 2005; Tashiro et al. 2007). Its 
gene amplification, rearrangement or overexpression has been described in breast, non-
small-cell lung, colorectal and esophageal cancer (Arber et al. 1996; Gillett et al. 1994; 
Jiang et al. 1992; Reissmann et al. 1999). In fact, cyclin D1 gene amplification occurs in 
15-20% of human mammary carcinomas and cyclin D1 is overexpressed in 50% of 
breast cancers (Deshpande et al. 2005). In addition, E-type cyclins are frequently 
overexpressed in human tumours, for example in breast cancer and gastric cancer 
(Akama et al. 1995; Keyomarsi et al. 1994). 
 
Tumour suppressor proteins p53 and Rb are commonly altered in human cancers. The 
gene encoding p53 is mutated in 50-55% of human cancers, and it is the most mutated 
gene in human cancers (Levine 1997; Sherr 1996; Sherr and McCormick 2002). Its 
inactivation inhibits its major role in apoptosis and cell cycle arrest in response to DNA 
damage. In addition, mutations in gene encoding Rb are common in various human 
cancers. Its hyperphosphorylation releases E2F transcription factors to activate genes 
required for S phase entry. The loss of Rb was originally identified in retinoblastoma, 
and thereafter in osteosarcoma, breast cancer and small cell lung cancer (Friend et al. 
1986; Friend et al. 1986; Harbour et al. 1988; Lee et al. 1988). 
 
4.2 Neurodegenerative diseases 
 
CDK5 is an unusual member of CDK family; it has only a little role in cell cycle 
regulation and it is not activated by cyclins (Dhariwala and Rajadhyaksha 2008; Dhavan 
and Tsai 2001). Instead, Cdk5 is highly expressed in the nervous system and it seems to 
be essential for neuronal survival and development. 
 
Like other CDKs, for activation CDK5 requires its regulatory partners, non-cyclin 
proteins, p35 or p39 (Tang et al. 1995; Tsai et al. 1994). CDK5-p35 and CDK5-p39 
phosphorylate numerous substrates involved in transcription, neuronal function, 
migration and synaptic transmission (Dhariwala and Rajadhyaksha 2008; Dhavan and 
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Tsai 2001). Most of them are associated with the cytoskeletal elements as signalling 
molecules or regulatory proteins.  
 
CDK5 plays an essential role in the development of central nervous system and 
neuronal differentiation (Chae et al. 1997; Ohshima et al. 1996). Mice lacking CDK5 
die just before or after birth and their brains display variety of neuronal positioning 
defects in cortex, hippocampus and cerebellum. In addition, mice lacking p35 display 
severe cortical lamination defects and suffer from seizures and sporadic adult lethality.  
 
Various neurotoxins lead to calpain-mediated conversion of p35 to p25 (Lee et al. 2000; 
Patrick et al. 1999). In contrast to p35, p25 is stable and has a much longer half-life. It is 
a neurotoxin that accumulates in neurons and constitutively activates Cdk5. Hyperactive 
CDK5-p25 complex phosphorylates cytoskeletal proteins leading to neuronal cell death. 
For instance, level of p25 is remarkably increased in brains of Alzheimer’s disease 
(AD) patients (Patrick et al. 1999). 
 
Deregulation of Cdk5 has been implicated in several neurodegenerative diseases, 
including AD, amyotrophic lateral sclerosis, Parkinson’s disease, Huntington’s disease 
and acute neuronal injury (Dhariwala and Rajadhyaksha 2008; Dhavan and Tsai 2001).  
 
The typical pathological feature of AD is brain atrophy caused by neuronal loss and 
formation of β-amyloid plaques and neurofibrillary tangles (Cruz and Tsai 2004; Tsai et 
al. 2004). In AD and several other neurodegenerative diseases, microtubule binding 
protein Tau is abnormally hyperphosphorylated. This hyperphosphorylation of Tau 
leads to its intracellular aggregation, called neurofibrillary tangles, which reduce Tau’s 
ability to associate with microtubules (Baumann 1993; Patrick et al. 1999; Paudel et al. 
1993). CDK5-p25 potently phosphorylates Tau, whereas CDK5-p35 poorly 
phosphorylates it. 
 
Another mechanism of AD pathology is the extracellular accumulation of fibrillogenic 
β-amyloid peptides that form amyloid plaques (Cruz and Tsai 2004; Selkoe 1999). This 
accumulation results from systematic cleavage of β-amyloid precursor protein (APP) by 
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secretases enzyme complex. CDK5 has been implicated to phosphorylate APP on Thr-
668 in the cytoplasmic domain (Iijima et al. 2000). Increased phophorylation of Thr-668 
is associated with APP processing and amyloid pathology. 
 
4.3 Cardiovascular diseases 
 
4.3.1 Atherosclerosis 
 
Cardiovascular diseases, with atherosclerosis as the underlying cause, are the most 
common reason for death in Western countries (Dzau et al. 2002; Glass and Witztum 
2001; Falk 2006). Atherosclerosis is a chronic progressive inflammatory disease that 
can convert into an acute clinical event by plaque rupture or thrombosis. In 
atherosclerosis; lipids, immune cells, fibrous elements and VSMCs accumulate into the 
intima of large and medium-sized arteries forming lesions. Atherosclerosis involves 
multifactorial processes including endothelial cell dysfunction, inflammation, 
extracellular matrix alteration and VSMC proliferation and migration.  
 
The vascular wall is composed of three layers (Figure 2) (Lusis Aldons 2000). Intima, 
the first layer from lumen, is mainly composed of extracellular matrix, such as collagen 
and proteoglycans. Intima is lined with a monolayer of endothelial cells on the luminal 
side and internal elastic lamina on the peripheral side. The middle layer, media, consists 
of smooth muscle cells (SMCs). The third layer, adventitia, is formed of connective 
tissues as well as fibroblasts and SMCs. 
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Figure 2. Structure of a normal large artery. Artery consists of three layers: intima, 
media and adventitia (adapted from Lusis 2000). 
 
Atherosclerotic lesions form preferably in specific arterial regions, such as branches and 
curvatures, where the blood flow is disturbed and pulsatile causing mechanical stress to 
the vessel wall (Cunningham and Gotlieb 2005; Gimbrone Jr. et al. 2000). This shear 
stress modulates endothelial structure and function for instance by increased endothelial 
permeability to lipoproteins, increased expression of adhesion molecules and reduced 
production of endothelial nitric oxide synthase (eNOS). All these alterations promote 
atherosclerotic lesion formation. 
 
The primary initiating event in atherosclerosis is the accumulation of lipids, mostly low 
density lipoproteins (LDL), into the intima, where they are modified by oxidation, 
lipolysis, proteolysis and aggregation (Lusis 2000; Ross 1999). Particularly, oxidation 
plays a critical role in atherogenesis (Steinberg 1997). Oxidatively modified LDL is 
found in lesions of atherosclerosis (Ylä-Herttuala et al. 1989). The accumulation of 
minimally oxidized LDL stimulate endothelial cells to produce various pro-
inflammatory molecules including growth factors and adhesion molecules such as 
vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 (Nakashima et 
al. 1998). Furthermore, these molecules contribute to monocyte migration into the 
intima, where they proliferate and differentiate into macrophages. Oxidized LDL is 
recognized by scavenger receptors and taken up into macrophages (Suzuki et al. 1997). 
These inflammatory responses contribute to the development of atherosclerosis. 
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Lipid-filled macrophages are called foam cells (Lusis 2000; Ross 1999). Foam cells and 
T lymphocytes form so-called fatty streaks, which are the earliest type of lesion and 
common already in infants and young children. Fatty streaks do not cause symptoms but 
they may further progress into more advanced, atherosclerotic lesions. They form the 
core of the lesion, which is surrounded by a fibrous cap. This cap contains VSMCs from 
media and collagen-rich matrix. Lesions continue to grow in response to VSMC 
proliferation and migration, extracellular matrix production and further lipid 
accumulation (Doran et al. 2008; Gerthoffer 2007; Glass and Witztum 2001). In 
addition, apoptosis of macrophages and VSMCs contribute the formation of the necrotic 
core. Development of advanced lesions is also contributed by inflammatory cytokines, 
matrix-degrading proteases and adhesion molecules. In addition, activated mast cells are 
found in atherosclerotic lesions (Kaartinen et al. 1994). They trigger matrix degradation 
and participate in the destabilization of the lesion, thus contributing to acute coronary 
events.  
 
Advanced lesions may contribute to plaque rupture and thrombosis, which lead to acute 
cardiovascular events such as myocardial infarction and stroke (Davies et al. 1993; Lee 
and Libby 1997). These complications occur generally in shoulder regions of the 
plaque, more likely in lesions with thin fibrous caps, large necrotic cores and high 
concentrations of lipid-filled macrophages. Other typical features of advanced lesions 
are neovascularisation and calcification influencing on the stability of lesion (Folsom et 
al. 2008; Moreno et al. 2006). 
 
4.3.2 Restenosis  
 
Restenosis is renarrowing of an artery dilated by percutaneous transluminal coronary 
angioplasty (PTCA). PTCA is the most common revascularization procedure for 
coronary artery disease (Bennett and O'Sullivan 2001; Weintraub 2007). Despite the 
pharmacological and technical development, it limits the long-term success of PTCA. 
Restenosis occurs in 30-50% of patients after balloon angioplasty and in 10-30% of 
patients received an intravascular stent. Luminal renarrowing leading to restenosis 
involves various biological processes, including elastic recoil, reorganization of 
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thrombus, inflammation, VSMC migration and proliferation, neointimal hyperplasia and 
vascular remodelling. After angioplasty, restenosis results primarily from vascular 
remodelling, whereas after stenting, neointimal formation seems to play a major role. 
 
Elastic properties of the vessel wall cause elastic recoil in response to the mechanical 
dilatation and overstretch (Rensing et al. 1991). It occurs straight after PTCA resulting 
in nearly 50% loss of luminal areas. This acute recoil can be reduced by stenting (Haude 
et al. 1993).  
 
Angioplasty and stenting cause mechanical stress that induces endothelial denudation, 
rupture of internal elastic lamina and medial dissection contributing to thrombus 
formation (Ip et al. 1990). Human studies of stented arteries have shown activation of 
platelets, fibrin and acute inflammatory cells early after stenting (Farb et al. 1999; 
Grewe et al. 2000; Komatsu et al. 1998). Activation of platelets leads to their adhesion 
and cross-linking by fibrinogen promoting their aggregation. Inflammatory cells, 
primarily macrophages, are found in the site of stent struts indicating the role of 
inflammation in restenosis. Consequently, mural thrombus forms on denuded arterial 
intima. 
 
Neointimal formation after injury occurs due to VSMC proliferation and migration and 
synthesis of extracellular matrix and collagen (Bennett and O'Sullivan 2001; Weintraub 
2007; Zargham 2008). Platelets, endothelial cells, macrophages and VSMCs release 
mitogens, chemoattractants and cytokines that promote VSMC proliferation after 
arterial injury. For example, PDGF, TGF-β, angiotensin II and EGF play important 
roles in intimal proliferation and matrix accumulation (Braun-Dullaeus et al. 1998). 
They also stimulate the proliferation of VSMCs. In addition VSMCs undergo 
phenotypic transition from contractile to synthetic, which facilitates their migratory 
activity (Zargham 2008). 
 
VSMCs seem to play a major role in restenosis after stenting (Moreno et al. 1999). 
SMC content was larger and proliferation index was higher in restenotic tissue after 
stenting than in restenotic tissue after PTCA. A significant change in neointimal 
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thickness has been observed three months after stenting with only a little change at six 
months (Asakura et al. 1998). When compared six months to three years after 
procedure, neointimal thickness was decreased significantly. In addition, thrombus 
occurred more often early after stenting and was not observed after three years. 
 
Vascular remodelling plays also an important role in development of restenosis (Bennett 
and O'Sullivan 2001). Remodelling is a normal process to maintain an appropriate 
lumen size, particularly in response to changes in blood flow, either constrictive 
(negative) or expansive (positive) remodelling. Already in early atherosclerosis, vessels 
are dilated in order to compensate the increasing intima (Glagov et al. 1987). Vessel 
wall remodelling has been determined to induce the majority of the lumen loss after 
angioplasty (Mintz et al. 1996). Remodelling may be caused by changes in extracellular 
matrix properties (Lafont et al. 1999). Angioplasty causes acute changes in extracellular 
matrix synthesis and degradation, resulting in increased collagen synthesis. 
 
 
5 CELL CYCLE AS DRUG TARGET IN CARDIOVASCULAR DISEASES 
 
Vascular proliferative diseases involve multifactorial and complex processes (Andrés 
2004; Braun-Dullaeus et al. 1998; Dzau et al. 2002). Cell cycle is the final pathway for 
signalling cascades that contribute cell proliferation. Accordingly, cell cycle regulators 
are more favourable target to inhibit cellular proliferation than a single mitogenic factor 
in upstream cascades. However, cell cycle regulation is very similar among various cell 
types, which complicates the specific targeting only at arteries. Cell cycle inhibition is 
possible to achieve by pharmacological agents, brachytherapy or gene therapy. So far, 
the therapeutic application of cell cycle inhibition has focused on inhibition of stent 
restenosis and bypass graft failure.  
 
Vascular gene therapy is a possible approach to modulate the cell cycle by various 
means such as antisense oligonucleotides, overexpression of specific genes or gene 
transfer (Bennett and O'Sullivan 2001; Dzau et al. 2002). For instance, transcription 
factor decoy oligonucleotides bear the consensus binding sequence of a specific 
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transcription factor, for instance E2F, whose function they can competitively prevent 
(Morishita et al. 1995). This modulation of gene expression inhibits smooth muscle 
proliferation and vascular lesion formation. 
 
Brachytherapy (β- and γ-radiation) is another approach to prevent cell proliferation. It 
has been shown to prevent neointimal formation and cell proliferation in stented vessels 
(Leon et al. 2001; Teirstein et al. 1997). Catheter-based intracoronary radiotherapy after 
coronary stenting substantially reduced the rate of restenosis (Teirstein et al. 1997). In 
addition, in another study the effects of brachytherapy were shown to persist for three 
years (Teirstein et al. 2000). 
 
The emphasis of pharmaceutical approach is to block the cell cycle progression without 
inducing cell death, thus to develop cytostatic molecules (Diaz-Padilla et al. 2009; 
Ivorra et al. 2003). Direct inhibition of the cell cycle by CDK inhibitors is a promising 
method to inhibit cell proliferation. The development of CDK inhibitors has mostly 
focused on treatment of cancer, but they might also be potent in treatment of 
vasculoproliferative diseases. Accordingly, the mechanisms behind the deregulation of 
cell proliferation in cancer and vasculoproliferative diseases are similar. In addition, 
indirect inhibition of cell cycle progression by inhibiting other regulatory mechanisms 
involved in cell proliferation is shown to be beneficial. For instance, both rapamycin 
and paclitaxel inhibit cell cycle indirectly. 
 
Systemic delivery of antiproliferative treatment is problematic, since it affects also 
nonvascular tissue (Sriram and Patterson 2001). Therefore, local delivery is preferred. 
For instance, drug eluting stents (DES) were developed for local intracoronary drug 
delivery. In contrast, especially CDK inhibitors have also been investigated for systemic 
delivery. 
 
5.1 Small molecular weight compounds as CDK inhibitors 
 
CDK inhibitors are low molecular weight compounds that compete with ATP for 
binding to ATP-binding site of the CDKs (Diaz-Padilla et al. 2009; Knockaert et al. 
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2002). This binding site differs substantially from that of other kinases, thus enabling 
high specificity to CDKs. CDK inhibitors are flat, hydrophobic heterocycles. They can 
inhibit the function of all CDKs without any selectivity or selectively inhibit the 
function of some specific CDK groups, for example CDK1, CDK2 and CDK5 or CDK4 
and CDK6. In treatment of vasculoproliferative diseases, absolute selectivity might not 
be the best approach. Therefore, targeting multiple steps in the same pathway or 
multiple pathways with similar downstream effectors might be more beneficial. 
 
Table 3. Selectivity of pharmacological CDK inhibitors. IC50 values of each compound 
are provided in micromolar concentrations (adapted from Knockaert et al. 2002, Ivorra 
et al. 2003). 
 
CDK inhibitor 
CDK1 – 
cyclin B 
CDK2 – 
cyclin A, E 
CDK4 – 
cyclin D 
CDK5 –  
p25 
GSK-3β 
Olomoucine 7 7 > 1000 3 100 
R-Roscovitine 
(Seliciclib, 
CYC202) 
0.45 0.7 > 100 0.16 130 
Flavopiridol 0.4 0.1 0.4 - 0.45 
Indirubin 10 
2.2 (A),  
7.5 (E) 
12 5.5 0.6 
Indirubin-3’-
monoxime 
0.180 
0.44 (A),  
0.25 (E) 
3.33 > 100 0.009 
Indirubin-5-
sulfonate 
0.055 
0.04 (A),  
0.15 (E) 
0.3 0.065 0.28 
 
 
On cultured cells CDK inhibitors might lead to cell cycle arrest in either G1 or G2 phase 
depending on the model and conditions such as concentration and cell line (Ivorra et al. 
2003). Various families of pharmacological CDK inhibitors have been identified 
including purines, flavonoids and indirubins (Table 3). 
 
5.1.1 Purines 
 
Substituted purines were discovered in systematic screenings of CDK1 inhibitors 
(Meijer and Raymond 2003). The first selective and potent CDK inhibitors were 
cytokinin analogues: olomoucine, roscovitine and purvalanols. Purine-based CDK 
inhibitors have been reported to inhibit CDK1, CDK2, CDK5, CDK7 and CDK9, but 
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exhibit no inhibitory activity against CDK4 and CDK6. Purine portion of these 
inhibitors binds to ATP-binding site of CDKs preventing the binding of ATP. 
 
R-roscovitine (CYC202, Seliciclib), a trisubstituted purine derivative, is a potent and 
broad-spectrum inhibitor of CDKs competing for the ATP binding site of the kinase 
(Meijer et al. 1997). It has been reported to inhibit CDK1, CDK2 and CDK5. Besides 
CDK inhibition, it has several additional effects. It inhibits phosphorylation of the 
carboxyl-terminal domain of RNA polymerase II possibly via its inhibitory effects on 
CDK7 and CDK9 (MacCallum et al. 2005; Whittaker et al. 2004). It has also been 
reported to decrease Rb phosphorylation at multiple sites in human colon cancer cells 
(Whittaker et al. 2004). In addition, it induces the accumulation of p53 (Ljungman and 
Paulsen 2001). In phase I trial in patients with refractory advanced solid tumours, higher 
doses of R-roscovitine induces unexpected toxicity (Benson et al. 2007). Hence, further 
studies will need careful optimization of the dose and schedule. 
 
5.1.2 Flavonoids 
 
Flavopiridol is a semisynthetic flavonoid derived from rohitukine, an alkaloid isolated 
from Dysoxylum binectariferum (Dai and Grant 2003; Diaz-Padilla et al. 2009). It was 
the first small molecular CDK inhibitor to enter clinical trials. Flavopiridol has been 
demonstrated to inhibit cell proliferation in various human tumour cell lines arresting 
cells in G1-S and G2-M phases. In vitro and in vivo studies have demonstrated that it 
inhibits several protein kinases, with the greatest activity against CDKs including 
CDK1, CDK2 and CDK4 (Carlson et al. 1996; Losiewicz et al. 1994). 
 
Flavopiridol has been indicated in inhibition of RNA polymerase II transcription by 
inactivation of CDK9-cyclin T1 (positive transcription elongation factor b) (Chao and 
Price 2001). In addition, it downregulates the activity of cyclin D1. It has been shown to 
inhibit the proliferation of human aortic SMCs in vitro and also the proliferation of rat 
carotid artery SMCs after balloon injury when administered orally (Ruef et al. 1999). 
Downregulation of cyclin D1 by flavopiridol has also been reported in breast cancer 
(MCF-7) and human osteosarcoma (U2OS) cell lines (Carlson et al. 1999). 
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Despite promising results from preclinical trials, generally flavopiridol has disappointed 
in clinical trials (Schwartz et al. 2001; Shapiro et al. 2001). Nevertheless, an 
optimization of administration schedule of flavopiridol led to clinical activity in chronic 
lymphocytic leukemia (Byrd et al. 2007). 
 
5.1.3 Indirubins 
 
Indirubin is the active component of a Quing Dai (indigo naturalis) that is called 
Danggui Longhui Wan in traditional Chinese medicine (Hoessel et al. 1999). This 
mixture of plants was used to treat chronic diseases such as leukaemia and 
inflammation. Indirubin has poor water solubility and low bioavailability, thus several 
derivatives with enhanced pharmacokinetic and pharmacologic properties were 
synthesized, including indirubin-3’-monoxime and indirubin-5-sulfonate.  
 
They are reported to inhibit potently CDK1 and CDK2 by binding to the ATP binding 
pocket of CDKs (Hoessel et al. 1999; Marko et al. 2001). This inhibition has led to the 
cell cycle arrest in G1-S or G2-M phase depending on cell type and concentration range. 
Indirubin derivatives have also been shown to inhibit GSK-3β (Leclerc et al. 2001). In 
addition, indirubin-3’-monoxime inhibited the phosphorylation of tau suggesting a 
beneficial effect in the prevention of AD (Leclerc et al. 2001). Indirubin-3’-monoxime 
has also been reported to inhibit VSMC proliferation and neointima formation in vivo 
(Schwaiberger et al. 2010). 
 
5.1.4 Future prospects  
 
Despite a significant effect on cell cycle of CDK inhibitors, there are several 
deficiencies regarding to their pharmacokinetic and pharmacologic profile (Diaz-Padilla 
et al. 2009; Malumbres et al. 2008). For example, it has been problematic to define an 
appropriate administration schedule with an acceptable toxicity profile. Hence, more 
potent and more selective molecules with preferable inhibition of certain subtypes of 
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CDKs are in development. These so-called second-generation CDK inhibitors are 
promising, but still in their early stages of clinical development. 
 
One attractive approach is to induce a synergistic effect by combination of a CDK 
inhibitor and a cytotoxic drug (Diaz-Padilla et al. 2009; Malumbres et al. 2008). 
Synergistic effect is highly dependent on administration schedule and sequence as 
observed in studies with flavopiridol together with antineoplastic agents (Bible and 
Kaufmann 1997). More pronounced synergy was reported when these agents were 
administered before flavopiridol. In another study, when administered after paclitaxel, 
flavopiridol was shown to enhance paclitaxel-induced caspase activation in the human 
gastric and breast cancer cell lines (Motwani et al. 1999). This potentiation was highly 
sequence dependent, thus pretreatment with flavopiridol antagonized the paclitaxel 
effect. In addition, flavopiridol combined with irinotecan was shown to be tolerable and 
safe with clinical activity against advanced solid tumours (Shah et al. 2005). On the 
contrary, flavopiridol combined with docetaxol in patients with metastatic breast cancer 
was reported to be unfeasible due to dose-limiting neutropenia (Tan et al. 2004). 
 
5.2 Pharmacological inhibitors in drug-eluting stents 
 
Bare-metal stents have been used in prevention of restenosis after angioplasty (Costa 
and Simon 2005; Kukreja et al. 2008). The major problem of bare-metal stents is that 
they are foreign bodies and act as a stimulus for cell proliferation and neointimal 
hyperplasia. DES coated with immunosuppressive or antiproliferative drugs were 
developed to improve clinical outcomes of coronary angioplasty. Rapamycin and 
paclitaxel were the first antiproliferative compounds used in DES. 
 
However, the major problem of DES seems not to be neointimal hyperplasia, but the 
delay in formation of protective endothelial cell layer to cover the stent (Finn et al. 
2007). Thus, the endothelial coverage is a powerful predictor of late stent thrombosis. In 
fact, DES were associated with an increased risk of late stent thrombosis and also 
increased rate of death as compared with bare-metal stents (Lagerqvist et al. 2007; 
Stettler et al. 2007). These results have stimulated the research to develop alternative 
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polymer coatings for permanent polymer such as biocompatible and bioabsorbable 
polymers (Kukreja et al. 2008). 
 
5.2.1 Rapamycin 
 
Rapamycin (sirolimus) is a natural macrocyclic lactone with potent immunosuppressive 
properties (Costa and Simon 2005; Kukreja et al. 2008). It was isolated from 
Streptomyces hygroscopicus in the mid 1970s. Rapamycin binds to FKBP12 (FK506-
binding protein 12), which is upregulated in human neointimal SMCs (Bjornsti and 
Houghton 2004; Schmelzle and Hall 2000). The FKBP12-rapamycin complex binds to 
mTOR inhibiting its activation. This inhibition blocks cell cycle progression at G1-S 
transition in VSMC (Marx et al. 1995). TOR is a serine/threonine kinase that plays a 
central role in regulation of cell growth and proliferation (Bjornsti and Houghton 2004; 
Schmelzle and Hall 2000). PI3K-Akt signalling pathway regulates the kinase activity of 
mTOR. Rapamycin has also been indicated in other cellular processes. For example, it 
has been reported to stabilize p27, which inhibits CDK2 kinase activity (Nourse et al. 
1994).  
 
Rapamycin has been shown to be effective in DES (Holmes Jr. et al. 2004; Morice et al. 
2002). It reduces neointimal proliferation, restenosis and associated clinical events 
compared with standard stents one year after implantation. It is now used in the 
sirolimus-eluting Cypher® stent. However, early and late stent thrombosis has been 
observed with sirolimus-eluting stents (Daemen et al. 2007). Especially diabetes was a 
strong predictor for stent thrombosis. 
 
Several rapamycin analogues including everolimus and zotarolimus have been 
developed for DES (Fajadet et al. 2006; Grube et al. 2004). Everolimus-eluting stent 
with bioabsorbable polymer was shown to effectively reduce neointimal hyperplasia 
and restenosis without observations of stent thrombosis (Grube et al. 2004; Serruys et 
al. 2009). However, both of these studies had small numbers of patients with standard-
risk lesions. Zotarolimus-eluting stent was also reported to reduce rates of clinical and 
angiographic restenosis without late stent thrombosis, but it was associated with a 
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significantly greater amount of neointimal hyperplasia compared with sirolimus-eluting 
stent (Fajadet et al. 2006; Miyazawa et al. 2008).  
 
5.2.2 Paclitaxel 
 
Paclitaxel is a diterpenoid compound, which was isolated from the bark of the Western 
yew tree in 1970s (Costa and Simon 2005; Kukreja et al. 2008). It binds specifically to 
the β-tubulin subunit of microtubules (Rowinsky and Donehower 1995). Microtubules 
form the mitotic spindle during cell division and are also important in other cell 
functions, including maintenance of cell shape, motility and intracellular transport. This 
inhibition results in accumulation of microtubule bundles with aberrant structures 
arresting cells in G2-M phase. Whether the effect is cytostatic or cytotoxic, depends on 
drug concentrations and duration of cell exposure (Kukreja et al. 2008).  
 
The paclitaxel-eluting stent Taxus® was shown to markedly reduce the risk of clinical 
and angiographic restenosis as compared with the bare-metal stent in nine months 
follow-up (Stone et al. 2004). However, paclitaxel-eluting stents have also been 
connected to stent thrombosis (Daemen et al. 2007). 
 
 
6 SUMMARY AND CONCLUSIONS 
 
The cell cycle is a complex process that involves numerous regulators either 
contributing or inhibiting the cell cycle progress. Its deregulation is connected to the 
development of various diseases including cancer, vasculoproliferative and 
neurodegenerative diseases. 
 
Cell cycle regulation has been extensively studied. However, it is not completely 
understood and new kinases involved in cell cycle regulation are identified. The main 
regulators include CDKs, cyclins, CKIs and their upstream regulators. Furthermore, the 
total function of CDKs is still under investigation. Besides cell cycle regulation, they 
play an important role in transcription and neuronal differentiation. On the other hand, 
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the role of CDKs in cell cycle regulation has been questioned not to be essential. 
Genetic studies in mice lacking a specific CDK or cyclin have revealed that not all 
CDKs are strictly essential for the cell cycle progression and that they can, at least 
partly, compensate for each other’s function. For instance, CDK2 has been shown to be 
dispensable for cell cycle progression. In addition, some CDKs have been shown to be 
essential for development of specific cell types or tissues and dispensable from others. 
 
The regulation of cell cycle, especially CDKs, has become a potent approach in 
treatment of cancer, cardiovascular and neurodegenerative diseases. Entry and 
progression through the cell cycle is one of the key events in vascular proliferative 
diseases. Hence, cell cycle regulation represents a promising but challenging target to 
treat these diseases. Few small molecular weight CDK inhibitors have reached to 
clinical trials in treatment of cancer but so far, none of them have been approved for 
commercial use. 
 
When developing CDK inhibitors to target cell proliferation, attention has to be paid to 
the activity of these compounds against other CDKs. It might be difficult to evolve truly 
selective CDK inhibitors for the cell cycle due the high homology of the ATP binding 
domains for example in CDK1, CDK2 and CDK9. In addition, the dispensability and 
compensability of CDKs must be taken into account in development of CDK inhibitors. 
 
Despite the promising results from pre-clinical trials, the clinical activity of CDK 
inhibitors has been limited with remarkable toxicity. In addition, many CDK inhibitors 
show in vitro and in vivo effects that can not be explained by the inhibition of CDKs, 
indicating other cellular functions. The aim is to design more potent and selective CDK 
inhibitors with inhibition of certain subtypes of CDKs. In addition, the pharmacokinetic 
and pharmacodynamic properties of existing CDK inhibitors have to be improved. 
Synergistic effect was observed when CDK inhibitors were administered sequentially 
with cytotoxic chemotherapy. Therefore, combination therapies might be effective in 
treatment of vasculoproliferative diseases. 
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More profound understanding of the complexity of cell cycle and its regulatory 
mechanisms is needed for its proper modulation. This knowledge may also reveal novel 
potential therapeutic targets. Careful investigation of existing CDK inhibitors benefits 
the development of more potent and more selective molecules with preferable 
pharmacokinetic profile. 
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EXPERIMENTAL PART 
 
 
INFLUENCE OF TYLOPHORINE 
ON HUMAN UMBILICAL VEIN SMOOTH MUSCLE CELL PROLIFERATION 
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1 INTRODUCTION 
 
1.1 Tylophorine 
 
Tylophorine belongs to phenanthroindolizidine alkaloids; a small group of plant natural 
compounds (Figure 3) (Li et al. 2001). It is the main active component of Tylophora 
indica (Asclepiadaceae), which was used in Ayurvedic medicine to treat allergic and 
inflammatory disorders. 
 
 
Figure 3. Chemical structure of (-)-R-tylophorine (adapted from Alexis Biochemicals, 
Axxora, 2011). 
 
Clinical trials of tylocrebrine, a positional isomer of (-)-R-tylophorine, as an anti-cancer 
agent failed in 1960s due to central nervous system toxicity, including ataxia and 
disorientation (Steerk et al. 2002). This disappointing result delayed further 
investigations of tylophora alkaloids. However, various analogues of tylophorine have 
recently been shown to inhibit the growth of several human cancer cell lines (Gao et al. 
2004; Wei et al. 2006; Wei et al. 2007). They showed potent cytotoxic activity against 
human hepatocellular carcinoma (HepG2), prostate (DU-145), breast (ZR-751) and both 
wild type (KB) and multidrug resistant (KB-Vin) nasopharyngeal cell lines (Gao et al. 
2004; Wei et al. 2006).  
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Tylophorine has recently been shown to arrest HepG2, human gastric (HONE-1), and 
human nasopharyngeal (NUGC-3) carcinoma cells in G1 phase by downregulating 
cyclin A2 expression (Wu et al. 2009). However, research has focused on tylophorine’s 
effect on cancer cells and there are no publications of tylophorine’s effect on VSMCs. 
Since tylophorine inhibits the growth of various cancer cells, it might be also promising 
in inhibition of VSMC proliferation. 
 
1.2 Background and aim of the work 
 
My supervisor Helge Joa has previously investigated the effect of (-)-R-tylophorine on 
rat aortic VSMCs. According to his results, tylophorine inhibits rat aortic VSMC 
proliferation concentration-dependently in calf serum stimulated cells with an IC50 of 
128 nM (± 44 nM) (Joa 2011). He has also shown that tylophorine downregulates cyclin 
D1 and p21 expression levels without affecting their mRNA levels. It has no effect in 
total p53 expression levels. Additionally, he has shown that tylophorine is a G1 phase 
arrestor in PDGF stimulated rat aortic VSMCs. 
 
All the experiments were performed in rat aortic VSMCs. Therefore, in order to exclude 
species specific effects of tylophorine, we tested its activity on human cells. The aim of 
my study was to investigate the effect of tylophorine on human umbilical vein smooth 
muscle cells (HUVSMCs). The main purpose of my study was to confirm the findings 
made with tylophorine in rat cells in HUVSMCs. Therefore, we were interested in the 
effect of tylophorine on HUVSMC proliferation, cell cycle progression and the 
expression of various cell cycle regulatory proteins. 
 
Additionally, my supervisor Joa has received the results from Pepchip™ kinase array. 
This kinase array was performed by the cooperation partners from Pepscan in the 
Netherlands. Hereby, whole cell extracts of tylophorine-treated and DMSO-treated 
VSMCs were examined with regard to their potential to phosphorylate selected peptide 
sequences (spotted on a chip), which were specific for a certain protein. The output data 
of this assay resulted in a list of proteins, in which the phosphorylation of a specific 
amino acid residue was modulated by tylophorine (in comparison to the DMSO-treated 
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control cells) as well as the list of suggested kinases responsible for these 
phosphorylations (APPENDIX). The data analysis revealed a 43-fold induction of p53 
phosphorylation on serine 9 by tylophorine. Therefore, one part of my work was to 
confirm this effect of tylophorine on p53 phosphorylation of serine 9 and also on other 
phosphorylation sites of p53 in cultivated HUVSMCs. 
 
 
2 MATERIALS AND METHODS 
 
2.1 Materials 
 
(-)-R-tylophorine was originally obtained from Department of Pharmaceutical Biology, 
University of Düsseldorf and later from Alexis Biochemicals. 1 µM tylophorine was 
used in all experiments except in the cell proliferation assay. 
 
All chemicals were obtained from Sigma Aldrich, Fluka or Carl Roth unless otherwise 
stated. Antibodies were mainly obtained from New England Biolabs and cell culture 
medium and supplements from Invitrogen and Lonza Group. All the chemicals were 
obtained from the following companies. 
 
Alexis Biochemicals (Switzerland) 
BIO-RAD Laboratories (Hercules, CA, USA) 
Carl Roth (Karlsruhe, Germany) 
New England Biolabs (Beverly, USA) 
Fluka (Buchs, Switzerland) 
Invitrogen (Carlsbad, CA, USA) 
Lonza Group Ltd. (Basel, Switzerland) 
Promega (Madison, USA) 
Roche Diagnostics, Penzberg, Germany 
Santa Cruz (Santa Cruz, USA) 
Sigma Aldrich (St. Louis, MO, USA) 
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2.1.1 Solutions and reagents 
 
 
Culture medium 
 
M231 (Invitrogen)  500 ml 
SMGS (Invitrogen)  25 ml 
 
 
Wash medium 
 
RPMI 1640 (Sigma Aldrich) 500 ml 
Benzylpenicillin/Streptomycin 5 ml 
  (Lonza Group Ltd.) 
 
 
Stop medium 
 
RPMI 1640   500 ml 
Benzylpenicillin/Streptomycin 5 ml 
Calf serum (Lonza Group Ltd.) 50 ml 
 
 
Starvation medium 
 
DMEM (Lonza Group Ltd.) 500 ml 
Benzylpenicillin/Streptomycin  (100 U/ml potassium penicillin /  
100 μg/ml streptomycin sulphate) 
L-glutamine (Lonza Group Ltd.) 200 mM 
Calf serum    500 µl 
 
PBS pH 7.4  
 
NaCl   36.0 g 
Na2HPO4   7.4 g 
KH2PO4   2.2 g 
ddH2O    ad 5000 ml 
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Lysis buffer (pH 7.5) 
 
Stock solution HEPES (50 mM)   25 ml 
  (Hydroxyethylpiperazineethanesulfonic acid)  
NaCl (50 mM)  25 ml 
NaF (50 mM)  1.05 g 
Na4P2O7 (10 mM)  2.23 g 
EDTA (5 mM)  25 ml 
  (Ethylenediaminetetraacetic acid) 
Na3VO4 (1 mM)  91.95 mg 
ddH2O   ad 430 ml 
Prior to use  Stock solution  430 µl 
PMSF (0.1 M in isopropanol) 5 µl 
  (Phenylmethanesulphonylfluoride) 
  Triton X-10 (10% in ddH2O) 50 µl 
  Complete™ 25x   20.2 µl 
  One tablet (Roche Diagnostics)  
  dissolved in 2 ml ddH2O) 
   
 
SDS 
   
Stock solution  Tris-HCl (0.5 M, pH 6.8)  37.5 ml 
  SDS   6.0 g 
Glycerol   30.0 ml 
Bromphenol blue  15.0 mg  
ddH2O   ad 100 ml 
Prior to use   Stock solution  85.0 ml 
  -Mercaptoethanol  15.0 ml  
 
 
Resolving gel 10% 
 
Freshly prepared 30% PAA   5 ml 
  Tris-HCl (1.5 M, pH 8.8)  3.75 ml 
SDS 10%   150 µl 
ddH2O    6.1 ml 
Prior to use   Temed (Tetramethylethylene diamine) 15 µl 
Ammonium persulfate 10% 75 µl 
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Stacking gel  
 
Freshly prepared 30% PAA    1.28 ml 
Tris-HCl (1.25 M, pH 6.8)  750 µl 
SDS 10%   75 µl 
ddH2O    5.25 ml 
Prior to use   Temed   15 µl 
Ammonium persulfate 10%  75 µl 
 
 
Electrophoresis buffer  
 
Stock solution (10x) Tris-Base   30 g 
Glycine   144 g 
SDS   10 g 
ddH2O    ad 1000 ml 
Prior to use  Stock solution (10x)  100 ml 
ddH2O    ad 1000 ml 
 
 
Blotting buffer  
 
Stock solution (5x) Tris- Base   15.2 g 
Glycine   72.9 g 
ddH2O   ad 1000 ml  
Prior to use   Stock solution (5x)  200 ml 
Methanol   200 ml 
ddH2O    ad 1000 ml  
 
 
TBS-T pH 8.0 
 
Stock solution (10x) Tris- Base   3.0 g  
NaCl   11.1 g 
Tween 20   1 ml 
ddH2O   ad 1000 ml 
Prior to use   Stock solution (10x)  100 ml 
ddH2O   ad 1000 ml 
 
 
Home-made ECL solution 
 
Stock solution H2O    4.5 ml  
TrisBase (1 M, pH 8.5)  500 µl  
Luminol (0.25 M in DMSO) 25 µl 
p-coumaric acid (90 mM in DMSO) 11 µl 
Prior to use  ddH2O2    3 µl 
 
  
39 
FACS (Fluorescence-activated cell sorter) buffer (pH 7.4) 
 
NaCl   40.6 g 
KH2PO4   1.3 g 
Na2HPO4   11.75 g 
KCl   1.4 g 
LiCl   2.15 g 
NaN3   1.0 g  
Na2EDTA   1.8 g 
ddH2O   ad 5000 ml 
 
 
Hypotonic fluorochrome solution 
      
Triton X-100 (in PBS)  0.1% (V/V) 
  Sodium Citrate  0.1% (W/V) 
  Propidium iodide 0.2% (W/V) 0.005% (W/V) 
 
 
2.1.2 Antibodies 
 
Primary antibodies 
 
Antibody  Source Dilution Provider 
Cyclin D1   Mouse 1:2000 New England Biolabs 
Cyclin E  Rabbit 1:1000 Santa Cruz 
CDK4  Rabbit 1:1000 Santa Cruz 
p21   Mouse 1:1000 Promega 
p53   Rabbit 1:1000 New England Biolabs  
phospho-p53 (Ser-6)  Rabbit 1:1000 New England Biolabs 
phospho-p53 (Ser-9) Rabbit  1:1000 New England Biolabs 
phospho-p53 (Ser-15) Rabbit  1:1000 New England Biolabs 
phospho-p53 (Ser-20) Rabbit  1:1000 New England Biolabs 
phospho-p53 (Ser-37) Rabbit 1:1000 New England Biolabs 
phospho-p53 (Ser-46) Rabbit 1:1000 New England Biolabs 
phospho-p53 (Ser-392) Rabbit 1:1000 New England Biolabs 
-tubulin  Mouse 1:2000 Santa Cruz 
 
 
Secondary antibodies 
 
Antibody  Source Dilution Provider 
Rabbit   Goat 1:2000 New England Biolabs 
Mouse  Goat  1:2500 Santa Cruz 
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2.1.3 Technical equipment and software 
 
Olympus CKX 31 Light Microscope 
Olympus Europe GmbH,  
Hamburg, Germany 
Vi-Cell™ XR Cell viability analyzer and 
cell counter 
Beckmann Coulter, 
 Fullerton, CA, USA 
TECAN Sunrise™ 96-well-plate reader TECAN, Mannedorf, Switzerland 
LAS-3000™ Luminescent image analyzer Fujifilm, Tokyo, Andpan 
FACSCalibur™ 
BD Biosciences Pharmingen,  
San Diego, Ca, USA 
AIDA™ (Advanced Image Data Analyzer) 
version 4.06 
Raytest GmbH,  
Straubenhardt, Germany 
GraphPad PRISM™ version 5.02 
GraphPad Software, Inc.,  
San Diego, Ca, USA 
LAS-3000™ Image Reader version 2.0 Fujifilm, Tokyo, Andpan 
Vi-Cell™ XR 2.03 Beckman Coulter, Fullterton, Ca, USA 
Light Microscope Olympus CKX 31 
Olympus Europe GmbH,  
Hamburg, Germany 
Mini-PROTEAN™3 Cell 
BIO-RAD Laboratories Hercules,  
CA, USA 
Power Pac™ HC power supply 
BIO-RAD Laboratories Hercules,  
CA, USA 
Mini Trans-Blot™ Electrophoretic 
Transfer Cell 
BIO-RAD Laboratories, Hercules,  
CA, USA 
 
 
2.2 Methods 
 
2.2.1 Cell culture 
 
HUVSMCs were kindly provided by Prof. Dr. David Bernhard (Medical University of 
Vienna, Vienna General Hospital). They were isolated from umbilical cords. Fresh cells 
at passage 4 were stored in aliquots of one million cells in liquid nitrogen at -196C.  
 
A cryovial containing approximately one million cells was taken out of liquid nitrogen 
and thawed in a 37°C water bath. The content of the vial was added into 75 cm
2
 plastic 
flask containing 15 ml pre-warmed culture medium, which was changed next day. 
 
  
41 
HUVSMCs were cultured in 75 cm
2
 or 150 cm
2
 plastic flasks, containing 15 or 30 ml 
culture medium, respectively, at 37°C and 5% CO2. They were passaged twice a week. 
Passages 3 to 8 were used. 
 
For passaging, all solutions were warmed in a 37°C water bath prior to use. Culture 
medium was discarded from the flask, cells were washed with wash medium and 
trypsinized with Trypsin/EDTA (Invitrogen) (0.05% / 0,02% in PBS) solution for 3 
minutes at 37°C. Trypsinization was stopped with stop medium and solution was 
centrifuged at 1200 rpm for 4 minutes. The supernatant was discarded and culture 
medium was added to the cells. Cell viability was counted from 500 µl sample with a 
Vi-CELL cell viability analyzer (Beckmann Coulter). The cells were seeded into 75 cm
2
 
(1.5x10
6
 cells/ml) or 150 cm
2
 (3.0x10
6
 cells/ml) plastic flasks for further cultivation. 
For experiments, cells were seeded into different culture dishes as stated below. 
 
2.2.2 Cell proliferation assay 
 
Resazurin conversion assay was used for assessment of cell proliferation. The metabolic 
activity of living cells was measured using resazurin, which is converted to fluorescent 
resofurin by viable cells. Therefore, the fluorescence is direct proportional to the 
amount of resazurin converting cells due to assumption that the metabolic rate is in all 
cells identical.  
 
HUVSMCs were seeded at 5000 cells/well in 96-well plates in culture medium. After 
24 h cultivation, the cells were treated with different concentrations of tylophorine or 
0.1% DMSO (Fluka). After 48 h incubation at 37°C, they were washed with starvation 
medium and then incubated in starvation medium containing 10 µg/ml resazurin (Sigma 
Aldrich) for 2 h. The samples were measured by monitoring the increase in fluorescence 
at wave length of 580-610 nm using excitation wavelength of 540-570 nm in a 96-well 
plate reader (TECAN). 
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2.2.3 Western blot 
 
Proteins involved in proliferative signalling pathways were analysed by western 
blotting. Western blot is a common method used for analysing alterations in protein 
expression levels. In addition, changes in the phopshorylation status of a protein are 
possible to investigate by using phospho-specific antibodies. 
 
Cells were seeded after passaging in 60 mm dishes (0.3 x 10
6
 cells/dish) and cultivated 
48 h. They were treated with tylophorine (1 µM) or vehicle (0.1% DMSO) for the 
indicated periods of time (15-120 min). The cells were placed on ice, washed with ice-
cold PBS and 100 µl ice-cold lysis buffer was added to the cells. After 5 minutes, the 
cells were scraped and lysates were transferred to labelled tubes. Samples were 
centrifuged at 13000 rpm for 10 minutes at 4°C. For protein quantification, 5 µl of 
supernatants were diluted in 45 µl H2O. To prepare protein samples, 90 µl of 
supernatants were mixed with 45 µl loading buffer and heated at 95°C for 5 min. All 
samples were stored at -20°C. 
 
Protein concentrations were determined by using the Bradford method (Bradford 1976). 
10 µl of samples were transferred to 96-well plate in triplicate and 190 µl of Bradford 
reagent, 1:5 dilution of Roti
®
-Quant (Carl Roth) in H2O was added to each well. 
Absorbance at 595 nm was measured with a TECAN Sunrise™ microplate reader. 
 
The protein samples were separated by discontinuous SDS-PAGE (sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis) (Laemmli 1970). For SDS-PAGE, 
resolving gel was first prepared and transferred into the gel cassette (BIO-RAD 
Laboratories) and stacking gel was prepared approximately after 30 minutes and 
transferred above resolving gel. A 15-well comb was inserted and the gel was allowed 
to polymerize at least for one hour.  
 
The gels were placed into the electrophoresis chamber filled with electrophoresis buffer 
and the comb was removed. Precision Plus™ protein standard (BIO-RAD Laboratories) 
and equal amounts of the proteins (25 μg) were added into the wells of stacking gel. 
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Proteins were separated by using a Mini-PROTEAN™ 3 Cell system (BIO-RAD 
Laboratories) connected to a Power Pac™ HC power supply (BIO-RAD Laboratories). 
Electrophoresis was performed at 110 V for 21 minutes or until the end of stacking gel 
and 200 V for 36 minutes. 
 
The proteins were transferred to Immuno-blot™ PVDF (polyvinylidenefluoride) 
membrane (BIO-RAD Laboratories) using Mini Trans-Blot™ Electrophoretic Transfer 
Cell system (BIO-RAD Laboratories) at 100 V for 90 minutes. The membranes were 
blocked with 5% fat free milk powder (Carl Roth) in TBS-T for one hour. After 
washing with TBS-T three times for 10 minutes, the membranes were incubated with 
specific primary antibodies in 5% fat free milk powder or in 5% BSA (Carl Roth) at 
4°C overnight. The membranes were washed with TBS-T (3 x 10 min) between 
incubations and detection. Then, they were incubated with respective horseradish-
peroxidase conjugated secondary antibodies for 2 hours at room temperature. A home-
made ECL solution was added to the membranes and proteins were detected with LAS-
3000™ luminescent image analyser (Fujifilm). Bands were quantified with AIDA™ 
software (Raytest). 
 
2.2.4 Flow cytometric cell cycle distribution analysis  
 
Flow cytometry was used to quantitate the DNA content of individual cells to assess the 
cell cycle distribution within cell populations. For this experiment, cells were stained 
with propidium iodide, a fluorescent dye, which binds to DNA (Riccardi and Nicoletti 
2006). 
 
Cells were seeded in 6-well plates (3 x 10
5
 cells/well) and treated with 1 µM 
tylophorine or 0.1% DMSO after 24 h cultivation. After the indicated time points (24-
120 h), supernatant of each well was transferred into the correspondingly labelled FACS 
tubes to collect also the cells that have detached during the incubation period. Attached 
cells were washed once with PBS, trypsinized with Trypsin/EDTA solution for 3 
minutes at 37°C. Trypsinization was stopped with stop medium and the cells were 
transferred into the tubes, which were centrifuged at 1400 rpm for 4 minutes at 4°C. 
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Supernatants were discarded and PBS was added into each tube. Tubes were vortexed 
thoroughly and centrifuged again as before. Supernatants were discarded and hypotonic 
fluorochrome solution buffer was added and tubes were incubated for 2 h at 4°C. 10 000 
cells were analysed by flow cytometry on a FACSCalibur
TM 
(BD Bioscience 
Pharmingen). 
 
 
3 RESULTS 
 
3.1 The effect of tylophorine on cell proliferation and cell cycle phases 
 
Resazurin conversion assay was performed to examine the effect of tylophorine on 
HUVSMC proliferation and to determine the concentration for 50% proliferation 
inhibition. Tylophorine inhibits HUVSMC proliferation dose-dependently with an IC50 
of 164 ± 50 nM (Figure 4). 1 μM tylophorine blocked the proliferation completely. 
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Figure 4. The effect of tylophorine on serum-stimulated HUVSMC proliferation. Cells 
were seeded one day before treatment with indicated concentrations of tylophorine or 
0.1% DMSO (control). After 48 h, cells were treated with resazurin for 2 h. Samples 
were measured by monitoring the increase in fluorescence at a wave length of 580-610 
nm using excitation wavelength of 540-570 nm in a 96-well plate reader (mean ± SD, 
n=3). 
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The potent antiproliferative action of tylophorine also becomes evident when observing 
cell density under the microscope over time (Figure 6). Whereas DMSO-treated cells 
almost reach confluence after 120 h, tylophorine-treated cells do not gain in density 
throughout the entire observation period. 
 
In order to investigate whether tylophorine interferes with cell cycle progression and 
arrests cells in a specific cell cycle phase, we performed flow cytometric cell cycle 
analysis. Figures 5 and 7 show the accumulation of HUVSMCs in S phase after 
tylophorine treatment at 24, 48 and 72 h when compared with DMSO treatment. With 
tylophorine treatment, cells accumulated in S phase over time, whereas after treatment 
with DMSO, cells accumulated in G1 phase. This accumulation of DMSO-treated cells 
was obvious after 72 h and presumably due to contact inhibition. Effect of tylophorine 
on cell density is clearly seen in microscopic pictures on Figure 6. 
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Figure 5. Effect of tylophorine on cell cycle distribution. Cells were seeded one day 
before treatment with 1 µM tylophorine or 0.1% DMSO. Cells were stained with 
propidium iodide after 24, 48 or 72 h and analysed by flow cytometry (mean ± SD, 
n=3). 
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Figure 6. Light microscopic analysis of tylophorine-treated HUVSMCs. Asynchronized 
serum-stimulated HUVSMCs were seeded one day before treatment with 1 µM 
tylophorine or 0.1% DMSO. Light microscopic pictures were taken every 24 h. 
 
 
 
 
 
 
 
 
 
 
 Tylophorine  DMSO 
24 h 
96 h 
72 h 
0 h 
48 h 
120 h 
  
47 
 
    
 
    
    
    
 
Figure 7. Cell distribution in asynchronized HUVSMCs. Cells were seeded one day 
before treatment with 1 µM tylophorine or vehicle (0.1% DMSO). Cells were stained 
with propidium iodide after 24, 48 or 72 h and analysed by flow cytometry. Results 
from one analysis are shown. Comparable results were obtained in three different 
experiments. 
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3.2 The effect of tylophorine on cell cycle regulatory proteins 
 
In order to confirm the downregulation of cyclin D1 by tylophorine observed in rat 
aortic VSMCs, we performed western blot analysis of protein samples obtained from 
HUVSMCs. Tylophorine treatment led to rapid degradation of cyclin D1 with first 
effects already seen 15 minutes after treatment (Figure 8). In addition, western blotting 
was used to determine the effect of tylophorine on several other cell cycle regulatory 
proteins. p21 expression levels were downregulated by tylophorine treatment, as 
demonstrated in Figure 8. The level of cyclin E and CDK4 did not change significantly 
(data not shown). Overall, tylophorine elicited comparable changes in the expression of 
cell cycle regulators in rat and human SMCs. 
 
 
 
 
 
Figure 8. Western blot analysis of tylophorine’s effect on cyclin D1 and p21 expression. 
HUVSMCs were seeded two days before treatment with 1 µM tylophorine or DMSO 
(0.1%) in indicated time points. As a control was a sample of HUVSMCs without 
treatment. One representative blot is shown. Consistent results were obtained in three 
separate experiments. 
 
 
3.3 The effect of tylophorine on p53 phophorylation 
 
The results of the kinase array led to the hypothesis that tylophorine treatment of 
VSMCs induces the p53 phosphorylation on serine 9 approximately 43-fold. Western 
blotting was used to confirm this outcome. Figure 9 demonstrates that p53 
phosphorylation on serine 9 is hardly detectable and not upregulated 43-fold by 
tylophorine as indicated in kinase array. Thus, we were not able to confirm the result of 
the kinase array in our cell system.  
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Furthermore, we performed western blot analysis on several other phosphorylation sites 
of p53. Tylophorine induces a reproducible dephosphorylation of p53 on serine 15. 
Results of other phosphorylation sites were not consistent (data not shown).  
 
 
 
 
 
 
Figure 9. Western blot analysis of tylophorine’s effect on phosphorylation of p53 on 
serine 9 and 15. HUVSMCs were seeded two days before treatment with 1 µM 
tylophorine or 0.1% DMSO in indicated time points. As a control was a sample of 
HUVSMCs without treatment. One representative blot is shown. Consistent results were 
obtained in three separate experiments. 
 
 
4 DISCUSSION 
 
4.1 The effect of tylophorine on cell proliferation  
 
Our experiments demonstrated that tylophorine inhibits HUVSMC proliferation dose-
dependently (IC50 164 nM ± 50 nM). Tylophorine has been shown to inhibit the growth 
of several cancer cell lines with IC50 values shown in Table 4 (Chuang et al. 2006; 
Steerk et al. 2002; Wu et al. 2009). Most of the studies have investigated the effect of 
(+)-S-tylophorine and tylophorine analogues. Only Steerk et al. (2002) showed the 
antiproliferative effect of (-)-R-tylophorine on cancer cells as we showed in 
HUVSMCs. The inhibitory concentrations of tylophorine are in a similar range in 
cancer cells and HUVSMCs. In addition, these concentrations are comparable to the 
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IC50 value obtained in rat aortic VSMCs (IC50 of 128 nM ± 44 nM) (Joa 2011). To 
conclude, tylophorine has a significant inhibitory effect on cell proliferation. 
 
 
Table 4. IC50 values of tylophorine in several cancer cell lines. Wu et al. and Chuang et 
al. have used (+)-S-tylophorine whereas Steerk et al. (-)-R-tylophorine. 
 
Cell line IC50 (nM) (mean ± SD) Reference 
HepG2 
human hepatocellular 
carcinoma 
237 ± 32 
Wu  
et al. 2009 HONE-1 
human nasopharyngeal 
carcinoma 
114 ± 6 
NUGC-3 human gastric carcinoma 134 ± 9 
MCF-7 human breast carcinoma 489 ± 45 
Chuang  
et al. 2006 
NCI-H460 human lung carcinoma 584 ± 39 
SF-268 
human central nervous 
system carcinoma 
1764 ± 105 
KB-3-1 
drug sensitive human 
nasopharyngeal carcinoma 
214 ± 60 
Steerk  
et al. 2002 
KB-V1 
multidrug resistant human 
nasopharyngeal carcinoma 
173 ± 45 
 
 
4.2 The effect of tylophorine on cell cycle regulatory proteins 
 
4.2.1 Cyclin D1 
 
We revealed that tylophorine reduces cyclin D1 expression levels. A small decrease in 
cyclin D1 level can already be seen after 15 minutes of tylophorine treatment, which 
indicates that tylophorine induces a fast downregulation of cyclin D1. 
 
My supervisor Joa has previously shown that tylophorine downregulates Cyclin D1 in 
rat aortic VSMCs (Joa 2011). In addition, he determined by qPCR (quantitative 
polymerase chain reaction) analysis that mRNA levels of cyclin D1 were unaffected in 
rat aortic SMCs after tylophorine treatment. This result suggests that the 
downregulation of cyclin D1 is not due to transcriptional inhibition but rather due the 
post-transcriptional regulation of cyclin D1. Furthermore, the experiments with 
proteasome inhibitor MG132 demonstrate that it blocks the downregulation of cyclin 
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D1 levels by tylophorine (Joa 2011). This indicates that tylophorine leads to 
downregulation of cyclin D1 via proteasomal degradation in rat aortic VSMCs. In 
addition, Joa later confirmed this result in HUVSMCs (Joa 2011). 
 
Cyclin D1 is a key regulator of G1 phase and initiation of cell cycle (Fu et al. 2004; 
Stacey 2003). Extracellular signals mediate its function as a gatekeeper of cell cycle 
from early to mid-G1 phase. In the initiation of S phase, cyclin D1 levels decrease 
automatically, which is necessary for DNA synthesis. It is a proto-oncogene. Its 
overexpression is known to correlate with the early onset of cancer and it is 
overexpressed in various cancer types including breast, bladder and lung cancer 
(Knudsen et al. 2006). For example, cyclin D1 has been determined to be overexpressed 
in breast cancer at high frequency without an increase in cyclin D1 gene copy number 
(Gillett et al. 1994). Therefore, its deregulation may be explained by other mechanisms 
including its defective regulation at the post-translational level such as deregulated 
degradation (Alao 2007). 
 
Cyclin D1 is highly unstable with a short half-life (~24 min) (Diehl et al. 1997; Diehl et 
al. 1998). It is mainly degraded by ubiquitin-dependent proteasomal pathway. This 
degradation depends on cyclin D1 phosphorylation on Thr-286, which was determined 
to be phosphorylated by GSK-3β. GSK-3β also triggers the relocalization of cyclin D1 
from the nucleus to the cytoplasma further contributing its inactivation. 
 
Various therapeutic agents that modulate the expression level of cyclin D have been 
studied primarily for anti-cancer therapy (Alao 2007). Only few of these agents have 
been considered for treatment of vasculoproliferative diseases.  
 
Rapamycin has been shown to inhibit cell proliferation, besides its other cellular 
mechanisms, by downregulating cyclin D1 expression in fibroblast (NIH3T3) and breast 
cancer (MCF-7 and MDA-MB-468) cell lines (Dong et al. 2005; Hashemolhosseini et 
al. 1998). Rapamycin affects both transcriptional and post-transcriptional regulation of 
cyclin D1. It delays the accumulation of cyclin D1 mRNA levels and affect cyclin D1 
ubiquitin-dependent degradation by stimulating the activation of GSK-3β. 
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Expression of cyclin D1 has also been shown to be decreased by flavopiridol in breast 
cancer (MCF-7) and human osteosarcoma (U2OS) cell lines (Carlson et al. 1999). This 
downregulation was observed by 6 hours and followed by the decline in CDK4 activity 
and the induction of retinoblastoma hypophosphorylation. Cyclin D1 decline was at 
least in part explained by decrease in cyclin D1 promoter activity that contribute to 
decreased cyclin D1 mRNA levels. 
 
We demonstrated that tylophorine induce rapid downregulation of cyclin D1 in 
HUVSMCs. As my supervisor Joa demonstrated, tylophorine leads to inhibition of 
proteasomal degradation of cyclin D1 in rat aortic VSMCs as well as in HUVSMCs 
(Joa 2011). However, further investigations are needed to determine the exact 
mechanism underlying the tylophorine-induced degradation of cyclin D1. 
 
4.2.2 p21  
 
According to our results, tylophorine decreases the expression of p21. p21 is an 
important CDK inhibitor and regulator of cell cycle (Chen et al. 1995; Harper et al. 
1993). For example, it mediates p53-dependent G1 arrest. However, p21 acts also as a 
positive regulator of the cell cycle (Labaer et al. 1997). Most of the cellular cyclin D1 -
dependent kinase activity is associated with binding to p21, although p21 was shown to 
inhibit cyclin D1-CDK4 kinase activity when expressed at higher concentrations. In 
addition, p21 has been determined to promote nuclear accumulation of cyclin D1-CDK 
complexes via inhibition of GSK-3β-triggered nuclear export of cyclin D1 (Alt et al. 
2002; Cheng et al. 1999). Therefore, p21 is essential for the activation of cyclin D1-
CDK complexes rather than inhibiting them. 
 
Such as cyclin D1, p21 is also a very unstable protein that is degraded by ubiquitin-
dependent proteasomal pathway (Bornstein et al. 2003). Phosphorylation of p21 at Ser-
130 stimulates its degradation. In addition, p21 is degraded in an ubiquitin-independent 
manner (Sheaff et al. 2000) 
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My supervisor Joa showed that p21 gene mRNA levels were not significantly altered by 
tylophorine, indicating that it has no influence on the transcription of p21 (Joa 2011). 
Therefore, these results may indicate that tylophorine affects both cyclin D1 and p21 
leading to their downregulation, which further interferes with the formation of an active 
cyclin D1-CDK4 complex.  
 
Tylophorine analogue DCB-3503 has been demonstrated to decrease the expression of 
cyclin D1, p21 and p53 in HepG2 cells (Wang et al. 2010). Earlier, it was shown to 
inhibit the growth of these cells (Gao et al. 2004). DCB-3503 induces rapid 
downregulation of cyclin D1, already after 15 minutes of treatment without affecting 
mRNA levels (Wang et al. 2010). These downregulations were suggested to result from 
translational modulations such as reduction in the rate of polypeptide chain elongation. 
Our results cannot completely rule out this as underlying mechanism for the 
tylophorine-mediated downregulation of cyclin D1 and p21 in VSMCs or HUVSMCs. 
 
Overall, tylophorine was identified to downregulate both cyclin D1 and p21 levels post-
translationally in a proteasome-dependent manner. The detailed mechanism underlying 
the decrease in both proteins needs further detailed investigation. 
 
4.2.3 Phosphorylation sites of p53 
 
Based on the kinase array, we assumed that p53 phosphorylation on serine 9 is 43-fold 
upregulated. However, we were not able to confirm this result in our cell system. 
Phosphorylation of p53 was hardly detectable. In addition, our other results of 
tylophorine’s effect on phosphorylation sites of p53 were not consistent. The only effect 
of tylophorine that was displayed was the slight decrease in the phosphorylation of p53 
on serine 15.  
 
One reason for our unfavourable results could be the inadequate amount of the protein. 
In addition, extremely low levels of phosphorylated p53 with inadequately sensitive 
antibodies may explain our unsatisfying results. Hence, it is possible that we were not 
able to detect the effect of tylophorine on p53 phosphorylation on serine 9, which was 
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predicted by the kinase array as upregulation. In order to completely clarify the issue of 
p53 phosphorylation at serine 9 and its susceptibility to tylophorine, more experiments 
are needed with more sensitive methods. 
 
p53 protein is an important regulator of cell cycle inducing cell cycle arrest and 
apoptosis (Levine 1997). Phosphorylation of p53 is associated with DNA damage and 
induction of apoptosis (Higashimoto et al. 2000; Mayo et al. 2005). My supervisor Joa 
showed by annexin V staining assay that tylophorine does not induce apoptosis (Joa 
2011). Our results from western blot analysis are unreliable, but also suggesting that 
tylophorine is not apoptotic. However, more experiments are needed to confirm this 
data. 
 
4.2.4 Other cell cycle regulatory proteins 
 
We investigated the effect of tylophorine on cyclin E and CDK4 expression levels but 
they were not changed. Consequently, there are only few publications on the effect of 
tylophorine on cell cycle regulatory proteins. Wu et al. (2009) investigated the effect of 
tylophorine on expression levels of various cell cycle regulatory proteins including 
cyclin A2, cyclin B1, cyclin E, CDK1, CDK2, CDK4 and p27 in asynchronized and 
synchronized HepG2, HONE-1 and NUGC-3 cells. They determined that tylophorine 
treatment downregulates cyclin A2 expression levels, whereas the level of other 
proteins did not change significantly. Furthermore, in synchronized cells arrested in G1-
S phase with double-thymidine, tylophorine treatment led to a reduction of cyclin A2 
level linearly over 24 h and also the mRNA level of cyclin A2 was significantly 
decreased. In addition, they determined that cyclin A2 promoter activity was decreased 
by tylophorine suggesting that it downregulates cyclin A2 expression through 
transcription. On the contrary, Joa determined that tylophorine treatment did not 
downregulate cyclin A in VSMCs (Joa 2011). This effect was not addressed in 
HUVSMCs. 
 
To conclude, tylophorine has a significant effect on several cell cycle regulators. 
However, the exact mechanism behind these effects needs to be examined. 
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4.3 The effect of tylophorine on cell cycle phases 
 
We investigated the effect of tylophorine on cell cycle distribution in asynchronized 
cells. Our experiments indicated an accumulation of HUVSMCs in S phase in the 
presence of tylophorine. Light microscopy observations indicated contact inhibition in 
DMSO treated cells after 120 h (Figure 6). It was also observed that there were no 
increase in density of tylophorine treated cells over 120 h, thus they were not dividing. 
These results indicate that tylophorine may retard the progression through S phase. 
 
FACS analysis upon propidium iodide staining alone is an inadequate method to 
precisely define the stage of an apparent cell cycle arrest. The amount of DNA in S 
phase cells varies and hence may be falsely added to G1 phase or G2-M phase. It is 
quite difficult to properly assign the gates for each cell cycle phase unless one is very 
experienced with this kind of analyses. Therefore, more profound analyses are needed 
to confirm the results. 
 
Joa had also investigated the effect of tylophorine on cell cycle distribution (Joa 2011). 
He showed an accumulation of quiescent PDGF-BB-stimulated VSMCs in G1 phase in 
the presence of tylophorine. This result was also confirmed by analysing the 
phosphorylation of Rb, which was completely blocked by tylophorine. In addition, he 
analysed asynchronized serum-stimulated VSMCs, which were shown to accumulate in 
S phase. The distribution of cells in G1, S and G2 phase was comparable to the 
distribution in HUVSMCs.  
 
Similar results were demonstrated by Wu and his colleagues (Wu et al. 2009). They 
investigated the effect of 2 µM tylophorine on cancer cell cycle by using both 
asynchronized and synchronized cells. According to their results, tylophorine arrests 
HepG2, HONE-1 and NUGC-3 carcinoma cells in G1 phase. Asynchronized cells 
accumulated in S phase. In synchronized cells, they used double-thymidine and 
thymidine-nocodazole to block the cells in G1-S and G2-M arrest, respectively. After 
release from G1-S or G2-M arrest, treatment with tylophorine led cells to arrest in G1 
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phase. They proposed that tylophorine inhibits carcinoma cell growth by dominantly 
arresting cells in G1 phase rather than retarding S phase progression. 
 
Gao et al. (2004) analysed the effects of (+)-S-tylophorine and its analogue DCB-3503 
on cell cycle progression in cancer cells. They showed a consistent increase in S phase 
in KB cells but no specific cell cycle arrest was observed in HepG2 cells. 
 
These results suggest that tylophorine retards the progression of S phase and arrest cells 
in G1 phase. It would be interesting to investigate cell cycle progression also in 
synchronized HUVSMCs whether tylophorine induces G1 arrest as observed in VSMCs 
and various cancer cells (Wu et al. 2009, Joa 2011). 
 
 
5 CONCLUSIONS 
 
The aim of this thesis was to evaluate the effect of tylophorine on HUVSMC 
proliferation and on expression of cell cycle regulatory proteins. We were able to 
demonstrate that tylophorine inhibits HUVSMC proliferation dose-dependently. 
Tylophorine downregulates cyclin D1 and p21 expression levels. This decrease in 
cyclin D1 was already seen after 15 minutes of tylophorine treatment. Effect of 
tylophorine on p53 phosphorylation sites remains unresolved and requires more 
sensitive methods to be completely unravelled. In our experiments, tylophorine was 
shown to induce the accumulation of HUVSMCs in S phase. 
 
There are several unanswered questions in tylophorine’s diverse effects on cell cycle 
and the underlying mechanism of action. However, tylophorine has significant effect on 
cell proliferation and cell cycle distribution. According to Joa’s results, the effect of 
tylophorine on cyclin D1 and p21 might be explained by proteasome-mediated 
degradation (Joa 2011). A number of investigations are needed in order to determine the 
specific mechanism of this degradation. In addition, the significance of tylophorine as 
cell cycle regulator and in treatment of vascular proliferative diseases and cancer 
requires more experiments in vitro and in vivo. 
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APPENDIX 
 
Results from Pepscan Pepchip™ kinase array  
PROTEIN  PSITE  Upstream kinase  Fold activation  
p53  S9  ATM + Casein_kinase_1,_alpha_1  43.70  
SMAD5  Y128  nd  3.57  
STAT5B  Y679  c-Src  2.35  
Metabotropic glutamate 
receptor 1  
T695  Protein_kinase_C_alpha  2.09  
Erythropoietin receptor  Y368  Janus_kinase_2  2.08  
6-phosphofructo-2-
kinase/fructose-2,6-
biphosphatase 2  
T475  Protein_kinase_C_alpha  1.87  
p47-phox  S348  Casein_kinase_II,_alpha_2 + 
Casein_kinase_II,_beta  
1.78  
RGS2  S46  Protein_kinase__cGMP-
dependent_type_I  
1.78  
SPIB transcription factor  S146  Casein_kinase_II,_alpha_1 + 
Casein_kinase_II,_alpha_2  
1.77  
Regulator of G protein 
signaling 19  
S151  ERK2  1.72  
Synuclein alpha  Y136  SYK  1.62  
Transcription factor IIA, 1  S280  Casein_kinase_II,_alpha_2 + 
Transcription_factor_IID  
1.62  
Stomatin  S10  -  1.59  
Formyl peptide receptor 1  S328  G_protein_dependent_receptor_kinase_2  1.56  
AFX 1  S196  AKT1  1.56  
HLA-A  S359  Protein_kinase_C_alpha  1.55  
Polo like kinase  T210  -  1.55  
FAS associated factor 1  S289  Casein_kinase_II,_alpha_1  1.53  
CTD phosphatase, subunit 
1  
S575  Casein_kinase_II,_alpha_2 + 
Casein_kinase_II,_beta  
1.48  
TBK1  S172  -  1.45  
ERK5  T218  -  1.42  
Protein phosphatase 
inhibitor 2  
S87  Casein_kinase_II,_alpha_1 + 
Casein_kinase_II,_alpha_2  
1.42  
E2F transcription factor 1  S403  Cyclin_dependent_kinase_7 + 
TFIIH_62_kDa_subunit  
1.42  
ZAP70  Y319  ZAP70  1.41  
Syntrophin alpha 1  S193  MAPK12  1.39  
Ribosomal S6 kinase 1  S230  3_Phosphoinositide_dependent_protein_
kinase_1 + 
Pyruvate_dehydrogenase_kinase,_ 
isoenzyme_1  
1.37  
Phosphatidylinositol 3-
kinase, regulatory gamma 
subunit  
Y341  -  1.35  
Eukaryotic translation 
initiation factor 4E  
S209  Protein_kinase_C,_beta_1 + 
Protein_kinase_C,_gamma  
1.34  
p21-activated kinase 7  S573  p21_activated_kinase_7  1.33  
LNK  Y273  Lck + ZAP70  1.33  
SHP2  S591  Protein_kinase_C,_beta_1 + 
Protein_kinase_C,_eta  
1.31  
 
